Protocol I3Y-MC-JPCY(b) 
CYCLONE 1: A Phase 2 Study of Abemaciclib in Metastatic Castration-Resistant 
Prostate Cancer Patients Previously Treated with a Novel Hormonal Agent and Taxane-
based Chemotherapy
[STUDY_ID_REMOVED]   
Approval Date: 04- Mar-2021 
CONFIDENTIAL I3Y-MC-JPCY (b)
1Title Page
Confidential Information
The information contained in this document is confidential and is intended for the use of clinical investigators.  It is the property of 
Eli Lilly and Company or its subsidiaries and should not be copied by or distributed to persons not involved in the cli nical 
investigation of abemaciclib (LY2835219 ), unless such persons are bound by a confidentiality agreement with Eli Lilly and 
Company or its subsidiaries.  
Note to Regulatory Authorities:   This document may contain protected personal data and/or commerc ially confidential 
information exempt from public disclosure.  Eli Lilly and Company requests consultation regarding release/redaction prior to any 
public release.  In the United States, this document is subject to Freedom of Information Act (FOIA) Exempti on 4 and may not be 
reproduced or otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries.
Protocol Title: CYCLONE 1: A Phase 2 Study of Abemaciclib in Metastatic Castration -
Resistant Prostate Cancer Patients Previously Treated wi th a Novel  Horm onal Agent and 
Taxane -based Chemotherapy
Protocol Number:   I3Y -MC-JPCY
Amendmen t: (b)
Compound :LY2835219
Study Phase: Phase 2
Short Title: Abemaciclib in Men wit h Heavily  Treated Metastati c Castrati on-Resistant Prostate 
Cancer
Acronym :JPCY
Sponsor Name: Eli Lilly and Com pany
Legal Registered Address: Indianapolis, Indiana ,USA 46285
Regulatory Agency Identifier Number(s)
IND: 139694
EudraCT:  2020 -000290-24
Approval Date: Protocol I3Y-MC-JPCY Electronically Signed and Approved by Lilly on18-
Mar-2020
Protocol I3Y-MC-JPCY(a) Electronically Signed and Approved by Lilly on24-Sep-2020
Protocol I3Y-MC-JPCY(b) Electronically Signed and Approved by Lilly ondate provi ded bel ow
Approval Date: 04-Mar-2021 GMT
CONFIDENTIAL I3Y-MC-JPCY (b)
2Medical Monitor Name and Contact Information will be provided separately .
Protocol Amendment Summary of Changes Table
DOCUMENT HISTORY
Document Date
Amendment (a) 24-Sep -2020
Protocol I3Y-MC -JPCY 18-Mar -2020
Amendment ( b)
This amendment is considered to be substant ial based on the cri teria set forth in Art icle 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council o f the European Unio n.
Overall Rationale for the Amendment:
Protocol amendment (b)for Study  JPCY protocol  was amended to update the dose m odificati on 
guidance and safet y monitoring. These updates are in alignment with changes made in the 
development core safet y informat ion of the Investigator’s Brochure (IB).
In addit ion, minor editorial changes have been m ade throughout the protocol to improve clarit y 
and practicabilit y of the protocol . 
Section # and Name Description of Change Brief Rationale
1.3. Schedule of Activities Added clarification to vital signs that 
procedure does not repeat edon Cycle 1 
Day1 if assessed at baseline ≤3 days prior 
to initiating abemaciclibAddition
1.3.1. Sampling Schedule for 
Pharmacokinetics and 
BiomarkersDeleted text from footnote b to align with 
Inclusion Criterion 9Deletion
5.3.Lifestyle Considerations Added ‘affect prostate specific antige n 
levels ’for participants who must not take 
preparations or herbal products and 
removed ‘endocrine effects’Addition
6.2.1 .Selection and Timing of 
DosesAdded language to discuss with Lilly 
CRP/CRS prior todispens ingadditional 
study treatmentAddition
6.5.Concomitant Therapy Updated language for CYP3A modulators 
and transporter substratesUpdate to align with current 
guidance
6.6.2 .Toxicity Dose Adjustments 
and Delays of AbemaciclibFormatted table for dose adjustments and 
delay s of abemaciclibFormatting; to align with IB 
update
6.6.2 .Dose Adjustments and 
Delays AbemaciclibAdded AST to the dose modification table 
for increased transaminasesTo align with IB update
Rem oved VTE specific guidance for dose 
modifications to follow non -hematologic 
dose adjustment guidanceTo align with IB update
CONFIDENTIAL I3Y-MC-JPCY (b)
38.2.2.2 .Guidance for Monitoring 
Renal FunctionUpdated renal function monitoring 
languageTo align with IB update
8.2.2.3. Guidance for Venous 
Thromboembolic EventsUpdated VTE safety monitoring language To align with IB update
8.2.2.4. Guidance for Interstitial 
Lung Disease/PneumonitisUpdated ILD/pneumonitis safety 
monitoring language To align with IB update
9.2. Sample Size Determination 
and Editorial changes to clarify study statistics Editorial
9.4.2 Primary Analysis
10.7.Appendix 7 Added A LT and A STto the CTCAE 5.0 
table and updated Appendix title and 
summary textto reflec t these additio nsAddition
CONFIDENTIAL I3Y-MC-JPCY (b)
4Table of Contents
1. Protocol Summary ...................................................................................................... 7
1.1. Synopsis ....................................................................................................................... 7
1.2. Schema ....................................................................................................................... 10
1.3. Schedule of Act ivities (SoA) ...................................................................................... 11
1.3.1. Sampling Schedule for Pharmacokinetics and Biomarkers .......................................... 22
2. Introduction .............................................................................................................. 24
2.1. Study  Rati onale .......................................................................................................... 24
2.2. Background ................................................................................................................ 25
2.2.1. Prostate Cancer ........................................................................................................... 25
2.2.2. Abemaciclib ............................................................................................................... 26
2.3. Benefit/R isk Assessment ............................................................................................ 27
2.3.1. Benefit Assessment ..................................................................................................... 27
2.3.2. Overall Benefit:  Risk Conclusio n............................................................................... 28
3. Objectives and Endpoints ......................................................................................... 29
4. Study Design ............................................................................................................. 31
4.1. Overall Design ............................................................................................................ 31
4.2. Scientific Rati onale f or Study  Design ......................................................................... 31
4.3. Justification for Dose .................................................................................................. 32
4.4. End of Study  Definit ion.............................................................................................. 32
5. Study Population ...................................................................................................... 33
5.1. Inclusio nCriteria........................................................................................................ 33
5.2. Exclusio n Cri teria....................................................................................................... 35
5.3. Lifest yle Considerat ions............................................................................................. 37
5.4. Screen Failures ........................................................................................................... 37
6. Study Intervention .................................................................................................... 38
6.1. Study  Intervent ion(s) Administered ............................................................................ 38
6.2. Preparati on/Handling/Storage/Accountabilit y............................................................. 38
6.2.1. Selection and Timing o f Doses ................................................................................... 39
6.3. Measures to Minimize Bias:  Rando mizat ion and Blinding ......................................... 39
6.4. Study  Intervent ion Compliance ................................................................................... 39
6.5. Concomitant Therapy .................................................................................................39
6.5.1. S upportive Care .......................................................................................................... 41
6.6. Dose Modificat ion...................................................................................................... 42
6.6.1. Dose Reductions for Abemaciclib ............................................................................... 42
6.6.2. Dose Adjustments and Delays Abemaciclib ................................................................ 43
6.7. Intervention after the End of the Study ........................................................................ 44
6.7.1. Study  Com pletion....................................................................................................... 44
6.7.2. Continued Access ....................................................................................................... 45
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal .................................................................................... 46
7.1. Discontinuati on of  Study  Intervent ion........................................................................ 46
CONFIDENTIAL I3Y-MC-JPCY (b)
57.2. Parti cipant Discontinuation/Wit hdrawal fro m the Study ............................................. 47
7.2.1. Discontinuati on of  Inadvertent ly Enrolled Participant s............................................... 47
7.3. Lost to Follow up ....................................................................................................... 48
8. Study Assessments and Procedures ......................................................................... 49
8.1. Efficacy Assessments .................................................................................................49
8.1.1. Definit ions of Efficacy  Measures ................................................................................ 49
8.1.2. Appropriateness of Assessments ................................................................................. 52
8.2. Safety Assessments .................................................................................................... 52
8.2.1. Clinical Safety  Laboratory  Assessments ..................................................................... 52
8.2.2. Safety Moni toring ....................................................................................................... 53
8.2.3. Safety Surveillance ..................................................................................................... 55
8.3. Adverse Events and Serious Adverse Events .............................................................. 56
8.3.1. Time Period and Frequency  for Collect ing AE and SAE 
Inform ation................................................................................................................. 57
8.3.2. Method of Detecting AE and SAEs ............................................................................. 57
8.3.3. Follow-up of  AEs and SAEs ....................................................................................... 58
8.3.4. Regulatory  Reporting Requirements for SAEs ............................................................ 59
8.3.5. Pregnancy ................................................................................................................... 59
8.3.6. Adverse Events of Special Interest .............................................................................. 59
8.3.7. Com plaint Handling ................................................................................................... 59
8.4. Treatment of Overdose ............................................................................................... 59
8.5. Pharmacokinet ics........................................................................................................ 60
8.5.1. Patient Diary ............................................................................................................... 60
8.6. Pharmacodynamics ..................................................................................................... 60
8.7. Genet ics..................................................................................................................... 60
8.7.1. Who le Blood Sample for Pharmacogenet ic Research .................................................. 60
8.8. Biomarkers ................................................................................................................. 61
8.8.1. Tissue Samples for Bio marker Research ..................................................................... 61
8.8.2. Other Samples for Bio marker Research ...................................................................... 62
8.9. Immunogenicit y Assessments ..................................................................................... 63
8.10. Health Economics ....................................................................................................... 63
8.10.1. Patient reported outcomes ........................................................................................... 63
8.10.2. Health Care Resource Utilizat ion................................................................................ 64
9. Statistical Considerations ......................................................................................... 65
9.1. Statistical Hypotheses .................................................................................................65
9.2. Sample Si ze Determinat ion......................................................................................... 65
9.3. Popul ations for Analyses ............................................................................................ 65
9.4. Statistical Analyses ..................................................................................................... 66
9.4.1. G eneral considerat ions................................................................................................ 66
9.4.2. Primary analysis ......................................................................................................... 66
9.4.3. Secondary  endpoint(s) ................................................................................................ 67
9.4.4. Exploratory  endpo int(s).............................................................................................. 67
9.4.5. Other Safet y Analyses ................................................................................................ 67
9.4.6. Other Analyses ........................................................................................................... 67
9.5. Interim Analyses ......................................................................................................... 69
9.6. Data Monitoring Committee (DMC) ........................................................................... 69
CONFIDENTIAL I3Y-MC-JPCY (b)
610. Supporting Documentation and Operational Considerations ................................ 70
10.1. Appendix 1:  Regulatory , Ethi cal, and Study  Oversight 
Considerations ............................................................................................................ 70
10.1.1. Regulatory  and Ethi cal Considerat ions........................................................................ 70
10.1.2. Financial Disclo sure................................................................................................... 70
10.1.3. Inform ed Consent Process .......................................................................................... 71
10.1.4. Data Protection ........................................................................................................... 71
10.1.5. Committees Structure .................................................................................................71
10.1.6. Data Qualit y Assurance .............................................................................................. 72
10.1.7. Source Documents ...................................................................................................... 73
10.1.8. Study  and Si te Start and Cl osure ................................................................................. 73
10.1.9. Invest igator Informat ion............................................................................................. 74
10.2. Appendix 2:  Clinical Laboratory  Tests ....................................................................... 75
10.3. Appendix 3:  Adverse Events:  Definit ions, and P rocedures for 
Recording, Evaluat ing, Follow -up and Reporting ........................................................ 77
10.3.1. Definit ion of AE......................................................................................................... 77
10.3.2. Definit ion of SAE ....................................................................................................... 78
10.3.3. Recording and Fo llow-Up of AE and/or SAE ............................................................. 79
10.3.4. Reporting of SAEs ...................................................................................................... 80
10.4. Appendix 4:  Contraceptive Guidance and Collection of 
Pregnancy Information ............................................................................................... 82
10.5. Appendix 5:  Liver Safet y:  Suggested Acti ons and Follow -up 
Assessments ............................................................................................................... 84
10.6. Appendix 6:  Inducers and Strong Inhibitors of CYP3A .............................................. 86
10.7. Appendix 7: CTCAE 5. 0 Diarrhea/Pneumo nitis/ALT and AST 
Increased Definit ions.................................................................................................. 87
10.8. Appendix 8:  Abbreviat ions........................................................................................ 88
10.9. Appendix 9:  Protocol Amendment History ................................................................ 93
11. References ................................................................................................................. 96
CONFIDENTIAL I3Y-MC-JPCY (b)
71. Protocol Summary
1.1. Synopsis
Protocol Title: CYCLONE 1:  A Phase 2 Study of Abemaciclib in Metastatic Castration -
Resistant Prostate Cancer Patients Previously Treated with a Novel Hormonal Agent and 
Taxane -based Chemotherapy
Short Title: Abemaciclib in Men wi th Heavily  Treated Metastatic Castration -Resistant Prostate 
Cancer
Rationale :
Prostate cancer is the second most commo n cancer in men and the f ifth leading cause of cancer 
deaths among men worldwide.  D espite the initialsensit ivity of advanced prostate cancer to 
androgen -deprivati on therapy ,most pati ents eventually develop castration -resistance .Persi stent 
or reactivat edandrogen receptor (AR) signaling and/or activat ion of pathways invo lved in 
crosstal kwith AR signaling are key  drivers of progressio nto metastatic castration -resistant 
prostate cancer (mCRPC) , an incurable and lethal stage of the disease .
The cyclin/cyclin -dependent kinase (CD K)/ret inoblastoma protein (pRb)-axis is a cri tical 
modulator of cell cycle entry  and is commo nly altered in cancer s.  Evi dence suggest sthat AR 
signaling prom otes enhanced translat ionof the D -type cyclins result ing in CDK4 and CDK6
(CDK4&6) activation, pRb hyperphosphorylat ion and cell cycle progression.
Abemaciclib is a n oral  and potent ATP -compet itive inhibitor of CDK4 &6 that is administered on
a continuous dosing schedule. Abemaciclib is approved by major gl obal regulatory  authori ties
for the treatm ent of  patients with horm one receptor -positive(HR+) ,human epidermal growth 
factor receptor 2 -negative (HER2 -)metastati c breast cancer (MBC) incombinat ion with an 
arom atase inhibitor as init ial endocrine -based therapy and wi th fulvestrant following endo crine 
therapy.  In addi tion, a bemaciclib is also approved as monotherapy  for heavily pre-treated
(following endocrine therapy  and chem otherapy ) HR+ , HER2 -MBC patients by the Food and 
Drug Administration.
Preclinical studies in cell cultures and mouse xenograft prostate cancer models showed that 
single agent abemaciclib induces cell cycle arrest and tumor growth inhibit ion(data on file) .The 
clinical act ivity of abemaciclib in co mbination wit h abiraterone and predniso ne is current ly 
investigated in a rando mized placebo -controlled Phase 2 study  in patientswith mCRPC 
(I3Y-MC-JPCM [ CYCLONE 2 ], [STUDY_ID_REMOVED]).
Treatment of advanced prostate cancer is palliat ive and therapeuti c options are limited for 
mCRPC patients whose disease had progressed afterlife-prolonging therapi es.Hence, there is 
an important unmet need for these patients that warrants the development of therapies with novel 
mechanism sof action.
This open -label single -arm Phase 2 study  will ass ess the safet y and efficacy of abemaciclib 
monotherapy  in heavily pretreated mCRPC patientswho received at least 1 novel hormonal 
agent and 2taxane regimens .
CONFIDENTIAL I3Y-MC-JPCY (b)
8Objectives and Endpoints
Object ives Endpoints
Primary
To characterize the efficacy of 
abemaciclib mo notherapy .Invest igator -assessed ORR per 
RECIST 1.1.
Secondary
To further characterize the clinical 
activit y of abemaciclib m onotherapy .rPFS
OS
DoR
DCR
PSA response rate
Time to PSA progression
Time to symptomatic progression
To characterize the safet y profile o f 
abemaciclib.Assessment of safet y including, but 
not limited to, the following:  AEs, 
SAEs, physical examinat ion,and 
clinical laboratory  abnorm alities per 
CTCAE v5.0
To expl ore pati ent reported tolerabilit y 
of abemac iclib mo notherapy  
(including symptomat ic AEs and 
overall side -effect burden), patient 
reported pain intensit y, physical  
funct ioning,and overall healt h related 
qualit y PRO- CTCAE 
FACT -GP5
7-day Worst Pain Numeri c Rat ing 
Scale
EORTC QLQ -C30 Physical 
Funct ioning Scal e
EORTC QLQ -C30 Gl obal Heal th 
Status/QoL Scale
To characterize the PK o f abemaciclib 
and its metabolites.Concentrations of abemaciclib and its 
metabo lites.
To characterize Ki-67 baseline 
expressio n% of cells expressing Ki -67 by  IHC
CONFIDENTIAL I3Y-MC-JPCY (b)
9Abbrevia tions:  AE = adverse event; CTCAE = Common Terminology Criteria for Adverse Events v5.0 (NCI 
2017); DCR = disease control rate; DoR = duration of response; EORTC -QLQ -C30 = European Organization for 
the Research and Treatment of Cancer Quality of Life Quest ionnaire; FACT -GP5 = Functional Assessment of 
Cancer Therapy -General; IHC = immunohistochemistry; Ki-67 = protein encoded by the MKI67 gene;
ORR =objective response rate; OS = overall survival; PK = pharmacokinetics; PSA = prostate specific antigen; 
PRO -CTCAE = Patient Reported Outcome -Common Terminology Criteria for Adverse Events v5.0 (NCI 2017); 
QoL = quality  of life; RECIST 1.1= Response Evaluation Criteria in Solid Tumors v ersion 1.1 (Eisenhauer et al; 
2009); rPFS = radiographic progression -free survival; SAE = serious adverse event.
Overall Design
CYCLONE 1 is an open -label, single -arm, global mul ti-center, Phase 2 study  to assess the safet y 
and efficacy of abemaciclib monotherapy  in patients with mCRPC. 
The study  popul ation consists of patients withprogressive mCRPC (by prostate -specific antigen 
[PSA]and/or imaging) who have previously received, in the metastati c horm one-sensi tivesetting
and/or in the castrati on-resistant setting s, at least 1 novel hormonal agent (abiraterone acetate , 
apalutamide ,darol utamide or enzal utamide ),and 2taxane regimens (docetaxel andcabazitaxel ).
Number of Participant s:
Approximately  40 participants wi th mCRPC will be treated in this study .
Intervention Groups and Duration:
Eligible participants will receive abemaciclib 200 mg orally twice daily on a continuous 28-day 
dosing schedule. Abemaciclib can be taken with or wi thout food, at approximately the same 
times each day, with at least 6 hours between doses.
Data M onitoring Committee: No
CONFIDENTIAL I3Y-MC-JPCY (b)
101.2. Schema
Abbreviations: mCRPC = metastatic castration resistant prostate cancer; n = number of participants; OS = overall 
survival ; PK = pharmacokinetics; PRO = patient reported outcome; PSA = prostate specific antigen; RECIST 1.1
= Response Evaluation Criteria in Solid Tumors versio n 1.1.;rPFS = radiographic progression -free survival .

CONFIDENTIAL I3Y-MC-JPCY (b)
111.3. Schedule of Activities (SoA)
This sect ion includes the fo llowing SoAs:
Screening, On- Treatm entand Post -Treatment SoA
Continued Access SoA
Sampling Schedule for Pharmacokinetics and Biomarkers
CONFIDENTIAL I3Y-MC-JPCY (b)
12Screening, On -Treatment and Post -Treatment Schedule of Activities 
Study phases ScreeningOn Treatment
Cycle duration = 28 daysPost-Treatment Follow -up Instructions
Baseline Cycle 1 Cycle 2Cycle 3 and 
subsequentShort -Term 
Follow -UpaLong -Term 
Follow -UpbProcedures and d isease assessments ( 
tumor imaging) should be performed as 
per the schedule of activit ies, according 
to the calendar days, regardless of 
treatment delays.
Relative Day within 
Dosing Cycle & 
Visit Window 
(±n days)≤28 ≤14D1
(±3)D15
(±3)D1
(±3)D15
(±3)D1
(±3)V801
(30 days ±7)V802 -8XX
(90 days ±14)
Documentation and Examination
Informed Consent XWritten informed consent must be 
obtained within 28 days prior to Cycle 1 
Day 1 AND prior to conducting any 
protocol -specific tests/procedures.
Inclusion/
Exclusion CriteriaX See Section s5.1and 5.2
Medical History XIncluding assessment of preexisting 
conditio ns, histo rical illnesses, prior 
anticancer therap ies(including systemic, 
local, and surgical), and habits (such as 
tobacco and alcohol use).
Prior and 
Concomitant 
MedicationX X XAt screening, record prior and concurrent 
medications. Record all premedication s, 
supportive care, and concomitant 
medication sincluding over -the-counter 
and analgesics use ,continuously at every 
visit and throughout the study.
Physical Examination X X X X X X XPerform prior to administering 
abemaciclib .Includes height (only at 
screening ) and weight .Does not need to 
be repeated on Cycle 1 Day 1 if assessed 
at baseline ≤3 days prior to abemaciclib
initiatio n.Additional exams should be 
CONFIDENTIAL I3Y-MC-JPCY (b)
13Screening, On -Treatment and Post -Treatment Schedule of Activities 
Study phases ScreeningOn Treatment
Cycle duration = 28 daysPost-Treatment Follow -up Instructions
Baseline Cycle 1 Cycle 2Cycle 3 and 
subsequentShort -Term 
Follow -UpaLong -Term 
Follow -UpbProcedures and d isease assessments ( 
tumor imaging) should be performed as 
per the schedule of activit ies, according 
to the calendar days, regardless of 
treatment delays.
Relative Day within 
Dosing Cycle & 
Visit Window 
(±n days)≤28 ≤14D1
(±3)D15
(±3)D1
(±3)D15
(±3)D1
(±3)V801
(30 days ±7)V802 -8XX
(90 days ±14)
performed as clinically indicated.
Vital Signs X X X X X X XPerform prior to administering 
abemaciclib .Collect temperature , blood 
pressure , pulse oximetry, andpulse rate .
Repeat if clinically indicated.
Does not need to be repeated on Cycle 1 
Day 1if assessed at baseline ≤3 days 
prior to abemaciclib initiatio n.
ECOG Performance 
StatusX X X X XDoes not need to be repeated on Cycle 1 
Day 1 if assessed at baseline ≤3 days 
prior to abemaciclib initiatio n.
Other Clinical Assessments 
12-Lead ECG X XSingle ECG performed locally. 
Participants must be supine for 
approximately 5 to 10 minutes before 
ECG collection and remain supine but 
awake during ECG collection. Repeat if 
clinically indicated .
AEAssessment X X X XCollect continuously at every visit and 
throughout the study using CTCAE 
Version 5.0. 
See Section 8.3for further details on AE 
and SAE reporting.
CONFIDENTIAL I3Y-MC-JPCY (b)
14Screening, On -Treatment and Post -Treatment Schedule of Activities 
Study phases ScreeningOn Treatment
Cycle duration = 28 daysPost-Treatment Follow -up Instructions
Baseline Cycle 1 Cycle 2Cycle 3 and 
subsequentShort -Term 
Follow -UpaLong -Term 
Follow -UpbProcedures and d isease assessments ( 
tumor imaging) should be performed as 
per the schedule of activit ies, according 
to the calendar days, regardless of 
treatment delays.
Relative Day within 
Dosing Cycle & 
Visit Window 
(±n days)≤28 ≤14D1
(±3)D15
(±3)D1
(±3)D15
(±3)D1
(±3)V801
(30 days ±7)V802 -8XX
(90 days ±14)
Laboratory Assessments
Hematology X X X X X X XSee Section 10.2, Appendix 2.  Does not 
need to be repeated on Cycle 1 Day 1 if 
assessed at baseline ≤3 days prior to 
abemaciclib initiation. Repeat if 
clinically indicated.   
Chemistry X X X X X X XSee Section 10.2, Appendix 2 .Does not 
need to be repeated on Cycle 1 Day 1 if 
assessed at baseline ≤3 days prior to 
abemaciclib initiation. Repeat if 
clinically indicated. Refer to Section s
8.2.2.1 and 10.5,Appendix 5,for hepatic 
monitoring.
PSA X X X X X See Section 10.2, Appendix 2.  
Testosterone X X X X X See Section 10.2, Appen dix 2.  
CONFIDENTIAL I3Y-MC-JPCY (b)
15Screening, On -Treatment and Post -Treatment Schedule of Activities 
Study phases ScreeningOn Treatment
Cycle duration = 28 daysPost-Treatment Follow -up Instructions
Baseline Cycle 1 Cycle 2Cycle 3 and 
subsequentShort -Term 
Follow -UpaLong -Term 
Follow -UpbProcedures and d isease assessments ( 
tumor imaging) should be performed as 
per the schedule of activit ies, according 
to the calendar days, regardless of 
treatment delays.
Relative Day within 
Dosing Cycle & 
Visit Window 
(±n days)≤28 ≤14D1
(±3)D15
(±3)D1
(±3)D15
(±3)D1
(±3)V801
(30 days ±7)V802 -8XX
(90 days ±14)
Tumor Assessment
CT o r MRI Scan of 
Chest, Abdomen, and 
PelvisXEvery 8 weeks , independent of treatment
delay s,
(Day  1 of Cy cle 3, 5, 7, 9, 11 , etc…)X XPerform w ithin 7 days prior to scheduled 
calendar day(except in screening 
period).
Unscheduled assessments if signs of
disease progression are observed.
Perform within 14 days of symptomatic 
progression (if no radiographic 
progression yet) and prior to the start of 
new anticancer therapy , palliative 
radiotherapy or surgery.
Patients discontinuing abemaciclib prior 
to documented radiographic progression 
will continue to have scheduled disease 
assessments until documented 
radiographic progression , start of new 
anticancer therapy, withdrawal of
consent, death, or study completion, 
whichever occurs first.Radionuclide Bone 
ScanXEvery 8 weeks , independent of treatment
delay s,
(Day  1 of Cy cle 3, 5, 7, 9, 11 , etc…)X X
CONFIDENTIAL I3Y-MC-JPCY (b)
16Screening, On -Treatment and Post -Treatment Schedule of Activities 
Study phases ScreeningOn Treatment
Cycle duration = 28 daysPost-Treatment Follow -up Instructions
Baseline Cycle 1 Cycle 2Cycle 3 and 
subsequentShort -Term 
Follow -UpaLong -Term 
Follow -UpbProcedures and d isease assessments ( 
tumor imaging) should be performed as 
per the schedule of activit ies, according 
to the calendar days, regardless of 
treatment delays.
Relative Day within 
Dosing Cycle & 
Visit Window 
(±n days)≤28 ≤14D1
(±3)D15
(±3)D1
(±3)D15
(±3)D1
(±3)V801
(30 days ±7)V802 -8XX
(90 days ±14)
MRI (preferred) or 
CT Scan of Brain XOnly required at screening for patients 
with suspicion and/or symptoms of CNS 
involvement to rule out CNS metastases.  
Unscheduled assessments if signs of 
CNS disease progression areobserved.
Symptomatic 
ProgressionX X X X XAssess: 
Symptomatic skeletal event defined
as sy mptomatic f racture, surgery, or
radiation to bone or spinal cord 
compression
Pain progression or worsening of 
disease -related symptoms requiring 
initiatio n ofa new sy stemic anti -
cancer therapy
Development of clinically significant 
symptoms due to lo co-regional tumor 
progression requiring surgical 
interventio n or radiation therapy
Perform until evidence of symptomatic 
disease progression, start of new 
anticancer therapy, withdrawal of 
consent, death, or study completion, 
whichever occurs first.
Study Treatment
CONFIDENTIAL I3Y-MC-JPCY (b)
17Screening, On -Treatment and Post -Treatment Schedule of Activities 
Study phases ScreeningOn Treatment
Cycle duration = 28 daysPost-Treatment Follow -up Instructions
Baseline Cycle 1 Cycle 2Cycle 3 and 
subsequentShort -Term 
Follow -UpaLong -Term 
Follow -UpbProcedures and d isease assessments ( 
tumor imaging) should be performed as 
per the schedule of activit ies, according 
to the calendar days, regardless of 
treatment delays.
Relative Day within 
Dosing Cycle & 
Visit Window 
(±n days)≤28 ≤14D1
(±3)D15
(±3)D1
(±3)D15
(±3)D1
(±3)V801
(30 days ±7)V802 -8XX
(90 days ±14)
AbemaciclibOrally twice daily ,on Days 1 through 28 of 
a 28-day cycle.See Section 6.1
Study Drug 
Compliance 
AssessmentX XAbemaciclib bottle(s) ,including any 
unused tablets ,will be returned at the 
beginning of ever y cycle starting at Cycle 
2 Day  1 and at abemaciclib
discontinuation for drug accountability
Review Patient Diary X X X XReview patient diary at each study visit 
for completion of date and time for each 
dose taken on the day before PK 
sampling. After Cycle 3 Day 1, the diary 
is no longer required. 
Post-study Treatment Collections
Post-Discontinuation 
Anti-Cancer 
TherapiesX XCollect until death , withdrawal of 
consent, or study completion.
Survival Status X XAlthough preferable to collect during a 
clinic visit, if no procedures are required, 
survival information may be collected by 
contacting the patient or family directly 
(e.g., via telephone.  This should be 
collected at minimum every 90 (±14) 
days if no other procedures are 
performed.
CONFIDENTIAL I3Y-MC-JPCY (b)
18Screening, On -Treatment and Post -Treatment Schedule of Activities 
Study phases ScreeningOn Treatment
Cycle duration = 28 daysPost-Treatment Follow -up Instructions
Baseline Cycle 1 Cycle 2Cycle 3 and 
subsequentShort -Term 
Follow -UpaLong -Term 
Follow -UpbProcedures and d isease assessments ( 
tumor imaging) should be performed as 
per the schedule of activit ies, according 
to the calendar days, regardless of 
treatment delays.
Relative Day within 
Dosing Cycle & 
Visit Window 
(±n days)≤28 ≤14D1
(±3)D15
(±3)D1
(±3)D15
(±3)D1
(±3)V801
(30 days ±7)V802 -8XX
(90 days ±14)
Pharmacogenomic , Biomarker and PD Assessment
Tumo r BiopsySee 
Section 
1.3.1See Section 1.3.1 See Section 8.8
PK Sampling
PK See Section 1.3.1 See Section 8.5
Patient Reported Outcomes
7-day Worst Pain 
NRSX X X X XSee Section 8.10
PRO questionnaires should be 
administered in the following order: 
7-day Worst Pain NRS, t hen 
PRO -CTCAE, then FACT -GP5, and 
finally  the EORTC QLQ -C30 Phy sical 
Functioning and Global Health 
Status/QoL scales.
PRO -CTCAE X X X X X See Section 8.10
CCI
CCI
CCI
CCI
CONFIDENTIAL I3Y-MC-JPCY (b)
19Screening, On -Treatment and Post -Treatment Schedule of Activities 
Study phases ScreeningOn Treatment
Cycle duration = 28 daysPost-Treatment Follow -up Instructions
Baseline Cycle 1 Cycle 2Cycle 3 and 
subsequentShort -Term 
Follow -UpaLong -Term 
Follow -UpbProcedures and d isease assessments ( 
tumor imaging) should be performed as 
per the schedule of activit ies, according 
to the calendar days, regardless of 
treatment delays.
Relative Day within 
Dosing Cycle & 
Visit Window 
(±n days)≤28 ≤14D1
(±3)D15
(±3)D1
(±3)D15
(±3)D1
(±3)V801
(30 days ±7)V802 -8XX
(90 days ±14)
FACT -GP5 X X X X X See Section 8.10
EORTC QLQ -C30 
Physical Functioning 
ScaleX X X X X See Section 8.10
EORTC QLQ -C30 
Global Health 
Status/QoLX X X X X See Section 8.10
Abbreviations: AE = adverse event; CNS = central nervous system; CT = computed tomography; CTC = circulating tumor cells; CTCAE = Common 
Terminology Criteria for Adverse Events (NCI 2017) ; D = day; ECG = electrocardiogram; ECOG = Eastern Cooperative Oncology Group (Oken et al. 1982) ; 
EORTC -QLQ -C30 = European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire; FACT -GP5 = Functional Assessment 
of Cancer Therapy -General; MRI = magnetic resonance imaging; n = number; NRS = numeric rating scale; PD = pharmacodynamics; PGx = 
pharmacogenomics; PK = pharmacokinetics; PRO = patient -reported outcome; PRO -CTCAE = Patient -reported outcome Common Terminology Criteria for 
Adverse Events;  PSA = prostate specific antigen; QoL = quality of life; SAE = serious adverse event ; V = visit .
aShort -term follow -up begins when the participant and investigator agree that the participant will no longer continue study treatment and las ts approximately 
30 days (±7 days).  
bLong -term follow -up begins when the short -term follow -up period is completed and continues until the participant’s death, los sto follow -up, or study  
withdrawal.  
In all cases, no follow -up procedures will be perfor med for a participant w ho withdraws informed consent unless he has explicitly provided permission and 
consent .
CONFIDENTIAL I3Y-MC-JPCY (b)
20Mobi le healthcare service may be leveraged to collect and process lab samples inconjunction with a patient’s visit , when deemed appropriate by the investigator
and allowed by local laws and regulations .
CONFIDENTIAL I3Y-MC-JPCY (b)
21Continued Access Schedule of Activities
Study phaseContinued Access Treatment Follow -upa
InstructionsV501-V 5XX V901
Procedure
Abemaciclib X Orally twice daily on Day s 1 through 28 of a 28 -day cycle.
AE collection X XAssessments to be conducted at a minimum with each collection 
and dispensing study drug (every 28 days) from Visits 501- 5XX. 
After V801 , only SAEs that are related to study intervention or 
protocol procedure will be collected. 
Frequency of evaluation, including efficacy assessments, is left to 
the judgement of the investigator based on standard of care. 
Abbreviation: AE = adverse event ; SAE = serious adverse event; V = visit .
aContinued access follow -up begins when the patient and the investigator agree that the patient will no longer continue abemaciclib in the continued access 
period and lasts approximately 30days.
CONFIDENTIAL I3Y-MC-JPCY (b)
221.3.1. Sampling Schedule for Pharmacokinetics and Biomarkers 
Sampling Day Tumor BiopsyPlasma andblood 
microsample
(PK)a
Baseline (Day −28 to Day  −1) Xb(mandato ry)
Cycle 1 Day  1 (Pre -dose)
Cycle 1 Day  1 (Post -dose) Xd
Cycle 1 Day 15 (Pre-dose) Xe
Cycle 2 Day  1(Pre-dose) Xe
Cycle 2 Day 15 (Pre-dose) Xe
Cycle 3 Day  1(Pre-dose) Xe
Cycle 4 Day  1 (any  time during visit)
End of treatment or Short -term follow -up (Visit 
801), prior to start of new anti -cancer therapyXg(optional)
Abbreviations:  eCRF = electronic case report form; CRP = clinical research physician; CRS = clinical research scientist; CTC = circulating tumor cells; 
PGx =pharmacogenomics ; PK =pharmacokinetics .
aThe date/time of the first abemaciclib dose on C ycle 1 Day 1 should be recorded in the eCRF.   After Cycle 1 Day 1, t he date and times (am/pm) of 
abemaciclib doses taken on the day prior toPK sampling should be recorded in the patient diary . 
bParticipants must have a metastatic lesion amenable to biopsy (core needle) for biomarker analysis.  Soft -tissue biopsy is preferred to bone biopsy whenever 
possible. Biopsy of newly emerged radiographic metastases preferred to biopsy of previou sly existing lesions whenever possible. Adequate archival 
metastatic tissue can be used in lieu of a new biopsy and if the biopsy was done within 12 weeks prior to enrollment and no treatment was initiated from 
biopsy to study entry.
c
dFor Cy cle 1 Day  1, PK sampling should occur any time 30 minutes after first abemaciclib dose . The blood microsample should be taken wi thin (+/-)
10 minutes of the plasma PK sample .  The date and times of all PK samples must be accurately recorded.
eFor Cy cle 1 Day  15 and all subsequent PK samples, PK sampling should occur in the morning before the first abemaciclib dose of the day. The blood 
microsample should be taken within (+/-)10 minutes of the plasma PK sample .The date and times of all PK samples must be accurately recorded.
f
CCI
CCI
CCI
CCI
CCI
CCI
CONFIDENTIAL I3Y-MC-JPCY (b)
23gOptional biopsy of metastatic lesion at the time of radiographic progression will be considered only if participant has completed at least 4 cycles of 
abemaciclib .The biopsy of a newly emerged or a progressing metastasis is preferred.
h
Mobile healthcare service may be leveraged to collect and process PK and  in conjunction with apatient’s visit ,when deemed 
appropriate by the investigator andallowed by local laws and regulations
CCI
CCI
CONFIDENTIAL I3Y-MC-JPCY (b)
242. Introduction
2.1. Study Rationale
Cyclin -dependent kinases 4 and 6 (CDK4 &6) inhibitors ha ve recent ly emerged as a standard of 
care for the management of horm one receptor -positive (HR+) , hum an epidermal  growth factor 
receptor 2 negative (HER2 -) metastati c breast cancer (MBC). Abemaciclib is an oral, select ive, 
and potent adenosine triphosphate ( ATP )-compet itive inhibitor of CDK4 &6that is dosed on a
continuous schedule .Abemaciclib is approved by major global regulatory authorit ies for the 
treatm ent of patients with HR+ , HER2 -MBC in combinat ion with an arom atase inhibitor (AI) as 
initial endocrine -based therapy  and wi th fulvestrant foll owing endocrine therapy .In addit ion, 
abemaciclib is also approved as monotherapy  for heavily pre -treated (fo llowing endocrine 
therapy  and chemotherapy) HR+, HER2 -MBC patients by the Food and Drug Administration 
(FDA).
Persi stent or reactivated androgen receptor (AR) signaling pathway through mo lecular 
adaptations (such as AR amplificat ion, overexpression, mutations, or the expressio n of 
constitutively act ive variants) and/or activat ion of pathways invo lved in crosstal kwith AR 
signaling are key  drivers of castrati on-resistant prostate cancer ( CRPC ). Similar to the estrogen 
receptor si gnaling pathway  in breast cancer, there is evidence that the ARsignaling pathway 
interacts wi th the CDK4 &6 and retinoblastoma protein ( pRb) axis to sustain prostate cancer cell 
proliferat ion and survival (Knudsen et al. 19 98; Xu et al. 2006).  It has been established that 
androgens induce cell- cycle progressi on, in part through mammalian target of rapamycin -
dependent translat ion of D- cyclins and subsequent activat ion of CDK4 &6 and pRb 
hyperphosphorylat ion (Xu et al. 2006). It was also suggested that upregulation of cyclin D1 is a 
potenti al mechanism of resistance to novel ant i-androgen agents (Pal et al. 2018). These findings 
suggest that CDK4& 6 may  play  an important rol e in the development and/or progression of 
prostate c ancer.
Preclinical studies in cell cultures and mouse xenograft prostate cancer models showed that 
single agent abemaciclib is effect ive in inducing cell cycle arrest and tumor growth inhibit ion
(data on file) .The clinical act ivity of abemaciclib in combinat ion with abiraterone and 
prednisone is current ly being investigated in I3Y-MC-JPCM ( CYCLONE 2), a randomized , 
doubl e-blind ,placebo -controlled Phase 2 study  in men with metastati c castrati on-resistant 
prostate cancer (mCRPC [[STUDY_ID_REMOVED] ]).
Ther e is a hi gh unmet m edical  needfor mCRP C pati ents whose disease progressed after novel  
horm onal agent(s) (NHA s) and chemotherapy ; thus, the development of tolerable and effect ive 
treatm ents wi th novel mechanism sof actionis warranted. Study  I3Y-MC-JPCY (CYCLONE 1)
is an open -label single -arm, mul ti-center, Phase 2 study  to eval uate the safet y and efficacy  of 
abemaciclib in thisheavily pretreated mCRPC patient popul ation.
CONFIDENTIAL I3Y-MC-JPCY (b)
252.2. Background
2.2.1. Prostate Cance r
Prostate cancer (PCa) is a leading cause of mortalit y and m orbidi ty globally, with more than 1.2 
millio n cases diagnosed and more than 359,000 deaths annually (Bray  et al . 2018) .  It is the 
second most commo nly diagnosed malignancy ,the fift h leading cause of cancer mortalit y in men 
and represents a substant ial public health burden (Bray  et al . 2018).   The m ajority of deaths from  
PCa are due to metastatic disease, ident ified either at diagnosis (de novo) or after relapse 
following local therapies.
Advanced PCa is an androgen -dependent di sease and tumorcells are primarily dependent on AR 
activit y for proliferat ion and survival.  Thus, a standard element in the treatment of patients with 
metastati c disease i s androgen deprivat ion therapy  (ADT), whi ch consists of bilateral 
orchi ectomy  or ini tiating a gonadotropin -releasing horm oneagonist or antagonist (GnRHa) as 
monotherapy  or in co mbinat ion with an ant i-androgen, also known as combined androgen 
blockade (Loner gan and Tindall 2011).
Based on the findings from the Phase 3 studies CHAARTED ([STUDY_ID_REMOVED]), STAMPEDE 
([STUDY_ID_REMOVED]), and LATITUDE ([STUDY_ID_REMOVED] ),all showing significant improvement in 
overall survival (OS ),the addi tion of  docetaxel or abiraterone acetate plus predniso ne to ADT is 
now considered a standard of care for men with high-volume or high-risk forms of metastatic 
horm one-sensit iveprostate cancer ( mHSPC ) (Sweeney et al. 2015; James et al. 2016, 2017; 
Fizazi et al. 2019 b).  In addition, the ARCHES ( [STUDY_ID_REMOVED]) andENZAMET 
([STUDY_ID_REMOVED]) studies with enzalutamide ,and the TITAN ([STUDY_ID_REMOVED]) study wit h 
apalutamide, recently demonstrated that addit ion ofenzalutami de or apal utamide to ADT 
improves progressi on–free survival (PFS) in patients with mHSPC (Armstrong et al. 2019; Chi et 
al. 201 8; Davis et al. 2019 ). Improvement of OS was also observed in ENZAMET and TITAN .
Advances in the management of non-metastati c castrati on-resistant prostate cancer (nmCRPC)
have also been recent ly reported. TheSPARTAN ([STUDY_ID_REMOVED] ), PROSPER ([STUDY_ID_REMOVED] ),
and ARAMIS ([STUDY_ID_REMOVED] )trialshave demo nstrated significant m etastases -free survival 
benefit withapalutamide, enzalutamide or darolutamide , respectively, plus ADT in men with 
nmCRPC and whose prostate specific ant igen ( PSA)doubling time was 10 m onths or less
(Hussain et al. 2018; Smit h et al . 2018; Fizazi et al. 2019 a). 
Despite these significant advances, nearly all pat ients with mHSPC or nm CRPC experience 
disease progressi on to m CRPC and cancer -speci fic m ortali ty.Overall, the mediansurvival from 
mCRPC diagnosis is less than 2 years (Higano et al. 2019).
The therapies approved for the treatm ent of mCRPC (reviewed by Nuhn et al . 2019) include :
Novel  horm onal agents with abiraterone acetate (wit h prednisone) or enzalutamide ,
α-emitting radium isotope radium- 223 (symptom atic bone m etastases and no known 
visceral metastatic disease) ,
Autologous cellular immunotherapy  sipuleucel -T (asymptomat ic or minimally 
symptom atic disease), and 
Taxane -based chem otherapy (docetaxel  orcabazitaxel, with predniso ne).
CONFIDENTIAL I3Y-MC-JPCY (b)
26The optimum treatm ent sequence has not been established and the clinical act ivity of secondary
NHAs (e.g. abiraterone after enzalutamide or the opposi te sequence) is modest, likely due to 
cross resistance mechanisms (Noonan et al . 2013; Schrader et al. 2014; Smit h et al . 2017 ). 
While chem otherapy  is a standard approach in this setting, it is oftenassoci ated wi th treatm ent-
limit ing toxicit ies.
Recent ly in the CARD study ,treatment with cabazitaxel demonstrated statistically significant 
radiographic progression free survival (rPFS) benefit over anti -androgen therapy (abiraterone or 
enzalutamide ) in participant s with mCRPC who were previously  treated wi th docetaxel and had 
progression wit hin 12 months while receiving the alternat ive inhibitor (abiraterone or 
enzalutamide [de Wi t et al . 2019 ]). The median rPFS was 8.0 months in the cabazitaxel group 
compared to 3.7 months i n the anti-androgen group ( hazard ratio 0.54; 95% confidence interval 
[CI], 0.40 to 0.73; p<.001). The median OS was 13.6 months in the cabazitaxel group compared 
to11.0 months in the anti-androgen group (hazard ratio 0.64; 95% CI, 0.46 to 0.89; p=.008 [de 
Wit et al . 2019 ]).  While t hese results support the use of cabazitaxel over abiraterone or 
enzalutamide in this setting , limited data exists to guide treatment for patients progressing after a 
NHA and taxane- based chemotherapy .
Amo ng the current unmet needs in prostate cancer, the lack of therapeut ic options for mCRPC
patients who exhausted life pro longing therapies is one of the most pressing ones .
2.2.2. Abemaciclib
During the cell cycle, the G1 restrict ion point con trols entry  into the S phase and is essent ial for
maintaining control of cell divisio n (Sherr 1996; Ortega et al. 2002). The cy clin-dependent
kinases (CDKs), CDK4 and CDK6 (CDK4&6) , parti cipate in a complex wit h D-type cyclins to 
initiate the transit ion through the G1 rest riction point by  phosphorylat ing and inact ivating the
tumor-suppressor retinoblastoma protein (pRb). Alterations in this pathway occur frequently in
human cancers and invo lve loss of CDK inhibitors by mutation or epigenet ic silencing, 
mutati on/overexpress ion of eit her CDK4 and CDK6 or cy clin D, or i nactivation of Rb. These
alterati ons may  render cells less dependent on mitogenic signaling for proliferat ion. From  a 
therapeuti c standpo int, the goal o f inhibit ing CDK4&6 with asmall molecule inhibitor i s to
prevent cell cycle progression through the G1 restrict ion point, thus arresting tumor growth.
Abemaciclib is an oral selective and potent ATP -compet itive inhibitor of CDK4 &6 that is 
administered on a continuous dosing schedule . The clinical activit y of abemaciclib has been 
extensively  studied in HR+, HER2 − MBC. 
Monotherapy  with abemaciclib (200 mg, twice daily on a continuous dosing schedule ) 
demonstrated meaningful antitumor activit y in heavily  pretreated refractory  HR+ , HER2− MBC 
patients wi th respons e rates of 19.7% and 28.6% observed in the single -arm Phase 2 study  
MONARCH 1 ([STUDY_ID_REMOVED]) and in therando mized Phase 2 study  NextMONARCH 1 
([STUDY_ID_REMOVED]), respectively  (Dickler et al . 2017 ;Hamilton et al. 201 9). 
In the randomized, placebo -controlled M ONARCH 2 Phase 3 study , the addi tion of  abemaciclib 
to fulvestrant provided a significant improvement of progression -free survival (PFS) 
(16.9 months versus 9.3 months, hazard ratio 0.536; 95% CI: 0.44 5, 0.645; p<.0001), OS 
(46.7 months versus 37.3 months, hazard ratio 0.757; 95% CI, 0.606- 0.945; p=.01) and object ive 
response rate (ORR) ( measurable disease: 48.1% versus 21.3%; 95% CI: 42.6 % to 53.6%; 
CONFIDENTIAL I3Y-MC-JPCY (b)
27p<.001) compared to placebo plus fulvestrant in HR+ , HER2− advanced or metastatic BC 
patients who progressed during prior endocrine therapy (Sledge et al . 2017; Sl edge et al . 2020). 
Of note, the OS benefit was consistent across subgroups including pat ients with a poorer 
prognosi s with visceral  metastases.
In the randomized, placebo -controlled MONARCH 3 Phase 3 study , the addi tion of  abemaciclib 
to a nonsteroidal AI as init ial treatment of HR+ , HER2− advanced or MBC patients provi ded a 
significant improvement of PFS ( 28.2 months versus 14. 8months; hazard ratio 0.540; 95% CI: 
0.418 to 0.698; p=.000002) and ORR ( measurable disease: 61.0% versus 45.5%; p=.003) 
compared to pl acebo pl us AI ( Goetz et al. 2018; Johnston et al. 2019). The OS data, an 
important secondary  end po int of this study , are immature.
Abemaciclib is current ly approved bymajor gl obal regul atory  authori tiesfor the treatment of 
patients wi th HR+, HER2 -advanced or MBC incombinat ion with an AIas init ial endocrine -
based therapy and wi th fulvestrant following endocrine therapy .  In addi tion, a bemaciclib is also 
approved a s monotherapy  for heavily pre-treated (following endocrine therapy and 
chemotherapy) HR+ , HER2- MBC patients by the FDA .
Using in vit roprostate cancer models , it has been shown that abemaciclib caninhibit pRb 
phosphorylat ionand arrest cells in G1 wit h evidence of subsequent senescence.   In AR+ 
xenograft models, single agent abemaciclib dosed daily demonstrated si gnificant ant itumor 
activit y.  
  In these studies, single agent abemaciclib showed evidence of ant itumor 
activit y relative to the vehicle in each model and the abemaciclib plus enzalutamide arm 
demonstrated increased ant itumor activit y compared to both single -agent arm s.  Al together, 
preclinical data suggests that abemaciclib monotherapy  coul d exhibi t clinical ant itumor activit y
in prostate cancer . 
2.3. Benefit/Risk Assessment
More detailed informat ionabout the known and expected benefits, risks, serious adverse events 
(SAEs) ,and reasonably ant icipated adverse events (AEs) of abemaciclib isto be found in the 
Invest igator’s Brochure ( IB).  Information on AEs expected to be related to abemaciclib may b e 
found in IB. Informat ion on SAEs expected in the study populat ion independent of drug 
exposure will be assessed by  the sponsor in aggregate periodically  during the course of the study  
and may be found in the IB .
More detailed informat ion about the known and expected benefits and risks of standard of care 
endocrine therapies, such as GnRH amay be found in the respect ive Patient Informat ion Leaflet, 
Package Insert, or Summary  of Product Characteristics.
2.3.1. Benefit Assessment
There i s a pressing unmet need for novel therapeutic agents in the care of mCRPC patients who 
experience disease progression fo llowing novel  horm onal agent(s) (androgen -synthesis or 
receptor inhibitor, such as abiraterone acetate , apalutamide ,darol utamide or enzalutamide and
taxane- based chem otherapy with docetaxel and cabazitaxel .In thislater-line setting, treatm ent 
options are limi ted and m ay include (where approved and if not previously  given) :
CCI
CCI
CCI
CONFIDENTIAL I3Y-MC-JPCY (b)
28An alternate novel hormonal agent (abiraterone or enzalutamide) -with possible acquired 
resistance and a potenti al limited benefit that needs to be considered .
Radium-223 (f or participant s with symptom atic bone metastases, and no known visceral 
metastati c disease ).
Poly (ADP-ribose) polymerase inhibitors, such as rucaparib or olaparib , for a sel ected 
popul ation (pati ents wi th homolo gous recombinat ion repair gene mutations), per the 
respective approved labels. 
Agents which have shown so me modest palliat ive benefits (such as mitoxantrone, 
corticosteroi ds, or other secondary  hormone therapy, such as ketoconazole,
diethylst ilbesterol [DES ], or other estrogens). 
Pembrolizumab in selected popul ations(patients wit h microsatellite instabilit y ‐high or 
mismatch repair ‐deficient tum ors)per theapproved label.
Clinical trials and best supp ortive care are addi tional options f or these patients who have 
exhausted , or are not eligible to receive, life-prolonging therapi es.
To the best of our knowledge, there are no historical control data for assessing treatm ent effects 
inthisheavily pretreated patient popul ationandclinical benefit obtained with treatm entoptions 
ment ioned above are likely to be of short duration .
In view of the potential ant itumor activit y of abemaci clibin the mCRPC popul ation, 
CYCLONE 1is designed to allow participant stocontinue therapy unt ildisease progressi on.
However, participant s maydiscont inue study  intervent ionat any  time if they choose to do so or 
if the invest igator believes it is in the best interest of the participant . Addit ionally , in the event of 
unacceptable toxicity, directions forreducing and/or discontinuing abemaciclib are provi ded. 
The assessment of patient-reported outcomes (PROs) will provide informat ion on participant s’ 
experience o f the treatment and will be part of the benefit -riskassessmen t.
This study  is being performed to assess the safet y and efficacy  of abemaciclib mo notherapy  in 
participant swith mCRPC whose disease progressed after at least 1 novel horm onal agent and 2 
taxane- based chemotherapy regimens .
2.3.2. Overall Benefit: Risk Conclusion
Taking into account the safet y profile of abemaciclib and the measures taken to minimize risk to 
participant s participating in this study , the potenti al risks i dentified in associat ion with
abemaciclib monotherapy  are justified by the ant icipated benefi ts that m ay be afforded to 
participant s with heavily pre -treated m CRPC .
The benefit / risk assessment, therefore, currently favors the proposed abemacicli bstudy  in 
participant s who exhausted mult ipleor all life prolonging therapies for prostate cancer.
CONFIDENTIAL I3Y-MC-JPCY (b)
293. Objectives and Endpoints
Object ives Endpoints
Primary
To characterize the efficacy of 
abemaciclib mo notherapy .Invest igator -assessed ORR per 
RECIST 1.1.
Secondary
To further characterize the clinical 
activit y of abemaciclib monotherapy .rPFS
OS
DoR
DCR
PSA response rate
Time to PSA progression
Time to symptomatic progression
To characterize the safet y profile o f 
abemaciclib.Assessment of safet y including, but not 
limited to, the fo llowing: AEs, SAEs, 
physical examinat ion,and clinical 
laboratory  abnorm alities per CTCAE 
v5.0
To expl ore patient reported 
tolerabilit y of abemaciclib 
monotherapy (including symptomatic 
AEs and overall side -effect burden ), 
patient reported pain intensit y, 
physical funct ioning,and overall 
healt h related qualit y of life PRO- CTCAE
FACT -GP5
7-day Worst Pain Numeri c Rat ing 
Scale
EORTC QLQ -C30 Physical 
Funct ioning Scale
EORTC QLQ -C30 Gl obal Heal th 
Status/QoL Scale
To characterize the PK o f 
abemaciclib and its metabolites.Concentrations of abemaciclib and its 
metabo lites.
To characterize Ki-67baseline
expressio n% of cells expressing Ki-67 by  IHC
Exploratory
CCI
CONFIDENTIAL I3Y-MC-JPCY (b)
30Object ives Endpoints
Abbreviations:  AE = adverse event; CTCAE = Common Terminology Criteria for Adverse Events v5.0 (NCI 
2017); DCR = disease control rate; DoR = duration of response; EORTC -QLQ -C30 = European Organization for 
the Research and Treatment of Cancer Quality of Life Questionnaire; FACT -GP5 = Functional Assessment of 
Cancer Therapy -General; IHC = immunohistochemistry; Ki-67 = protein encoded by the M KI67 gene;
ORR= objective response rate; OS = overall survival; PK = pharmacokinetics; PSA = prostate specific antigen; 
PRO -CTCAE = Patient Reported Outcome -Common Terminology Criteria for Adverse Events v5.0 (NCI 2017); 
QoL = quality of life; RECIST 1.1 = Response Evaluation Criteria in Solid Tumors v ersion 1.1 (Eisenhauer et al; 
2009); rPFS = radiographic progression -free survival; SAE = serious adverse event; SSE = symptomatic skeletal 
event .
CCI
CONFIDENTIAL I3Y-MC-JPCY (b)
314. Study Design
4.1. Overall Design
CYCLONE 1 is aPhase 2 open -label, single -arm, mul ti-center study to assess the efficacy of 
abemaciclib monotherapy  inparticipant s with mCRPC whose disease progressed on or after a t 
least 1 androgen -axis therapy (abiraterone acetate, apalutamide, darolutamide or enzalutamide) 
and2 taxane -based chemotherapy regimens ( docetaxel andcabazitaxel ).Participants m ay have 
received up to 3 prior systemic treatments for mCRPC, must have measurable disease per 
Response Evaluat ion Cri teria in Solid Tumors (RECIST )versio n 1.1, and a metastati c lesion 
amenable to biopsy .  Androgen deprivation therapy with a Gn RHamust be continued throughout 
the study for parti cipants who have not undergone bilateral  orchi ectom y.Abemaciclib 200 m g
twicedaily  will be administered on a continuous dosing schedule until disease progression, 
unacceptable toxicit y, or other discont inuat ion criteria are m et. 
This study  will initially treat approximately 40 participant s.
4.2. Scientific Rationale for Study Design
Patients whose mCRPC has progressed on or after priorNHA (s)and2taxane -based 
chemotherapy regimens represent a populat ion with high unmet m edical  need.
In the recent CARD study ([STUDY_ID_REMOVED]) ,treatm ent with cabazitaxel 25 mg/m2(with 
prednisone 10 mg daily  and p rimary prophylactic granulocy te-colony stimulat ing factor[G-CSF]
at every  cycle)offered stati stically significant rPFS benefit over ant i-androgen therapy
(abiraterone or enzalutamide ) in parti cipants wi th mCRPC who were previously treated with 
docetaxel and progressed wi thin 12 months while r eceiving the alternat ive inhibitor (abiraterone 
or enzalutamide [ de Wit et al. 2019 ]). The median rPFS was 8.0 months in the cabazitaxel group
compared to 3.7 months in the anti-androgen group (hazard ratio 0.54; 95% CI, 0.40 to 0.73; 
p<.001). The principal reasons for the discontinuation of treatment with cabazitaxel or the anti-
androgen therapy were disease progression (in 43.7% and 71.0% of the patients, respectively) or 
an AE(in 19.8% and 8.9% of the pati ents, respecti vely). The median OS was 13.6 months in the 
cabazitaxel group compared to 11.0 months in the anti-androgen group (hazard ratio 0.64; 95% 
CI, 0.46 to 0.89; p=.008 [de Wit et al. 2019 ]). 
While t hese results support the use of cabazitaxel over a second NHA in this setting, as y et, there 
are limited data to guide treatment for mCRPC patients experiencing disease progression after 
receiving a NHA, docetaxel and cabazitaxel .  This represents a high unmet medical need, as 
there was no standard of care for th ese patients .Of interest , in CARD, only about half (53.5%) 
of the pati entsin the cabazitaxel group receive da subsequent anticancer treatment ,23.2% 
crossed over to receive a second hormonal agent (abiraterone or enzalutamide), 14.7% received 
palliat ive radiat ion, 4.7% received radium-223,4.7% were enrolled in clinical trials to receive an 
investigat ional drug and 1.6% received docetaxel as re- challenge (de Wit et al. 2019 ).
The single arm, open label design for this study  is justified as current ly there are limited standard 
therapies wi th dem onstrated activit y forthe study  popul ation.
CONFIDENTIAL I3Y-MC-JPCY (b)
32Due to thenonoverlapping mechanism o f action of abemaciclib when com pared to currently 
approved therapies, and given its preclinical anti-proliferat ive effects on prostate cancer cell lines 
and x enograft models,the clinical activit y and manageable safety  profile as m onotherapy  
observed in heavily treated HR+ , HER2- MBC , abem aciclib may o ffer clinical benefit to the 
study  popul ation.This Phase 2 study  will evaluate the safety  and efficacy of abemaciclib
monotherapy  in the post -NHA (s)and post-chemotherapy mCRPC setting.
4.3. Justification for Dose
The maximum tol erated dose for abemaciclib mo notherapy  was defined in Phase 1 studies
I3Y-MC-JPBA and I3Y-MC-JPBC (Japanese participants) as 200 mg every 12 hours , whi ch 
demonstrated acceptable safet y and tol erabilit y in participant s with solid cancers (Patnai k et al . 
2016) . Abemaciclib mo notherapy  is approved by  the FDA for heavily pretreated HR+,HER2 -
MBC .  The m onotherapy  indicat ion is based on MONARCH 1 ([STUDY_ID_REMOVED]) where 
abemaciclib 200 mg twice daily  demonstrated a 19.7% (95% CI: 13.3, 27.5) ORR and median 
PFS of 6.0 months (Dickler et al .2017).
, in CYCLONE 1, abemaciclib monotherapy  will be administered 
orally  at 200 mg twice daily on Days 1 through 28 of a 28
-day cycle.
4.4. End of Study Definition
This s tudy will beconsidered complete (that is, scient ific evaluation will be co mplete [study  
completion] fo llowing the evaluat ion of all primary  and secondary  endpoints, as determined by 
Lilly. Invest igators will cont inue to follow the study schedule for all participant s unt il notified 
by Lilly  that study  com pletion has occurred. “End of Study” refers to the date of the last visit or 
last scheduled procedure for the last participant .
CCI
CCI
CONFIDENTIAL I3Y-MC-JPCY (b)
335. Study Population
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, isnot permitted.
5.1. Inclusion Criteria
Parti cipants are eligible to be included in the study only if all o f the following criteria are met :
1.Adult m ale(age ≥18 years or country's legal age of majorit y), who m ust be, in the 
judgement of the invest igator, an appropri ate candidate for experimental therapy .
Parti cipants m ust be capable of giving signed informed consent as described in Secti on 
10.1, Appendix 1, which includes co mpliance wit h the requirements and restrict ions 
listed in the informed consent form (ICF) and in this protocol.
2.Histologically confirmed adenocarcinoma of the prostate. Well -different iated 
neuroendocrine carcino ma, small cell or large cell neuroendocrine carcino ma, 
sarcomatoid, and carcino id tumors are excluded.
3.Metastatic prostate cancer documented by  positive bo ne scan and/or computed 
tomography  (CT) or m agnet ic resonance imaging (MRI). Presence of at least 1 
measurable lesion perRECIST v1.1(Eisenhauer et al. 2009) . Previously irradiated 
lesionsthat did not show radiographic progression after radiat ion therapy , primary  
prostate l esion and bone l esions will be considered non -measurable disease. If lymph 
node m etastasi s is the only  evidence of metastasi s, it must be at l east 1.5 cm  in the short 
axis. 
4.Serum  testosterone ≤1.73 nm ol/L (≤ 50 ng/dL) at the sc reening visit. Participant s who 
have not undergone bilateral orchiectomy are required to continue ADT with a GnRHa
throughout the study .
5.Progressive disease despite castrate level of serum testosterone based on at l east 1 of the 
following criteria :
Prost ate specific antigen (PSA) progression per Prostate Cancer Clinical Trials 
Working Group 3 ( PCWG3 )criteria for tri al eligibili ty:A sequence of at least 2 
rising PSA values at a minimum o f 1-week intervals, with the last value being at 
least 1.0 ng/mL.
Radiographic progressi on per RECIST v1.1 for soft tissue and/or per PCWG3 for 
bone ( appearance of≥2 new bone l esionson bone scan ), with or wi thout PSA 
progression .
CONFIDENTIAL I3Y-MC-JPCY (b)
346.Parti cipants must have previously received in the metastati c horm one-sensi tive setting 
and/orinthe castrati on-resistant setting s:
 At least 1 novel androgen receptor -axis therapy with abiraterone acetate, 
apalutamide, darol utamide or enzal utamide
AND
 2 taxane regimens . A taxane regimen is defined as at least 2 cy cles of docetaxel 
or cabazitaxel. Re-challenge withdocetaxel will not be considered a second 
taxane regimen .
If a participant has not received a second taxane regimen, the participant may still be 
eligible after discussio n and approval by the Lilly  clinical research physician/scient ist 
(CRP/CRS) if:
o Parti cipant has history of hypersensit ivity react ions or intolerance to docetaxel, 
cabazitaxel, drugs formulated with polysorbate 80 or to corticosteroids
or
o Parti cipant has any contraindicat ion or preexisting condit ion not compat ible 
with receiving an addit ional taxane therapy  per local prescribing informat ion
or
o Parti cipant experienced taxane- related AErequiring treatm ent discont inuat ion 
or did not y et resolve to Grade ≤1 (except alopecia).
Thereason must be recorded in the participant ’s medi cal notes and medical history  in the 
electroni c case report form (eCRF ).  
7.Parti cipants may  have received up to 3 prior systemic therapy  regimens in the metastatic 
castration -resistant setti ng.
NOTE:  GnRHa , first-generation ant iandrogens (flutamide, nilutamide, or bicalutamide) , 
DES (or other estrogens) , corticosteroids, ketoconazole, and bone loss -prevent ion will 
not coun t as sy stemic therapy  regimens.
8. Except for GnRHa and bone loss -prevent ion treatment, participant smust have 
discontinued previous anti-cancer agents at least 21 day s (or 5 half -lives ,whichever is 
shorter ) prior to treatm ent init iation.Participants must have recovered from acute toxic 
effects of prior therapy , palliat ive radiat ionor surgical procedure to Grade ≤1 or baseline 
(as per Commo n Termino logy Criteria for Adverse Events [ CTCAE ] v 5.0) , with the 
exception of alopecia or peripheral neuropathy .
9.Must be willing and amenable to undergo tumor biops y of at least 1metastati c site, 
which shoul d be collected fo llowing determinat ion of eligibilit y and before init iating 
study  treatm ent.
Soft tissue biopsy  is strongly  preferred to bone bio psy whenever possible.
CONFIDENTIAL I3Y-MC-JPCY (b)
35Biopsy  of newly emerged radiographic metastases preferred to biopsy  of 
previously exist ing lesions whenever possible.
Adequate archival metastatic tissue can be used if available in lieu of a new 
biopsy if the biopsy  was done wi thin 12 weeks prior to enrol lment andno 
treatm ent was init iated fro m biopsy  to study entry .
10.Have Eastern Cooperative Onco logy Group (ECOG) Performance Status of 0-1(Oken et 
al. 1982) and adequate organ funct ion, as defined below:
System Laboratory Value
Hematologic
ANC≥1.5×109/L
G-CSF shoul d not be administered to meet ANC 
eligibilit y criteria.
Platelets ≥100×109/L
Hem oglobin≥9 g/dL
Parti cipants may receive eryt hrocy te transfusio n to 
achieve this hemoglo bin level at the discretion of the 
investigator. Initial treatm ent m ust not begin earlier than 
the day  after the ery throcyte transfusio n.
Hepatic
Total  bilirubin ≤1.5 ×ULN OR
<2.0 ×ULN for participant swith history  of 
unconjugated hyperbilirubin emia(Gilbert’s syndrome )
ALT and AST ≤ 3×ULN 
Abbreviations:  ALT = alanine transaminase ; ANC= absolute neutrophil count; AST = aspartate transaminase ; 
dL = deciliter; G -CSF = granulocyte -colony -stimulating factor; g = gram; L= liter; ULN= upper limit of normal. 
11. Sexually  active participant s,with a female partner who is of child -bearing potential ,
must agree to use a medically  approved contraceptive method during the study  and for at 
least 3 weeks fo llowing the last dose of abemaciclib (e.g., intrauterine device, 
nonhorm onal birth control  pills, or barrier method).  If condoms are used as a barrier 
contraceptive, a spermicidal agent should be added as double barrier protection. Please 
refer to Section 10.4 ,Appendix 4 ,for addi tional reproductive and contraceptive 
guidance.
5.2. Exclusion Criteria 
Parti cipants are excluded fro m the study  if they meet ANY of the f ollowing cri teria:
12.Prior treatm ent wi th abemaciclib or any  CDK4 and/or CDK 6 inhibitors .
CONFIDENTIAL I3Y-MC-JPCY (b)
3613. C urrent ly enro lled in a clinical study invo lving an investigat ional product or any  other 
type of medical research judged not to be scient ifically or medically  com patible wit h 
this study .  Have participated in any clinical trial for which treatment assignment is still 
blinded unless agreed by  the Lilly  CRP/CRS. If a participant is current ly enro lled in a 
clinical trial invo lving non -approved use of a device, then agreement with the 
investi gator and the Lilly  CRP/CRS is required to establish eligibilit y.
14.Have ahistory ofanyothercancer (except nonmelano maskin cancer orcarcino main-
situofany origin), unless incompleteremissio nwithnotherapy for aminimum of 
2years.
15.Serious and/or uncontrolled preexist ing medical condit ion(s) including but not limited 
tosevere renal impairment (for example, estimated creatinine clearance <30 mL/min ), 
severe hepatic impairment (Child -Pugh C), interstitial lung disease (ILD) /pneumo nitis, 
severe dyspnea at rest or requiring oxygen therapy . Other serious preexist ing medical 
condi tion(s) that, in the judgment of the investigator, would preclude participation in this 
study (such as history  of major surgical  resecti on invo lving the stomach or small bowel , 
or preexisting Crohn’s disease or ulcerative co litis, preexist ing chronic condit ion 
resul ting in Grade ≥2 diarrhea, gastrointestinal disorder affect ing absorption or inabilit y 
to swallow medicat ion).
16. H istory of any of the f ollowing condit ions within the last 12 months: syncope of 
cardi ovascular eti ology,ventricular arrhy thmia of pathol ogical ori gin (including, but not 
limited to, ventricular tachy cardi a and ventri cular fibrillat ion), or sudden cardiac arrest .  
17.The participant has act ive systemic infect ions (for example, bacterial infect ion requiring 
intravenous [IV] antibiot ics at time o f initiating study  treatm ent, fungal  infect ion, or 
detectable viral infect ion requiring systemic therapy) or viral load (such as known 
human i mmunodeficiency virus positivit y or wi th known act ive hepat itis B or C [for 
example, hepatit is B surface ant igen posit ive]).  Screening is not required for 
enrollment.
18.Known or suspected central nervous system (CNS) metastatic disease (baseline 
screening for CNS m etastases i s not requi red unless there is presence of signs and/or 
symptoms of CNS involvement).
19.Untreated spinal cord compressio n or evidence of spinal metastases with risk of spinal
compressi on. Structurally unstable bone lesio ns suggesting im pending fracture.
20.Estimated l ife expectancy < 4 m onths as assessed by  the investi gator .
CONFIDENTIAL I3Y-MC-JPCY (b)
375.3. Lifestyle Considerations
Parti cipants shoul d refrain fro m consuming grapefrui ts or grapefruit juice while on study  
intervent ion.
Parti cipants m ust not take preparations orherbal products thought to affect PSA levels 
(such as ,saw palmetto or pom egranate ).
Parti cipants m ust not donate bl ood or sperm  during the study  and f or 3 months after the 
last study  interventi on dose.
Parti cipants wi th known hypersensit ivity or suspected i ntolerance to abemaciclib or any 
of itsexcipients (e.g .,lactose) should not take abemaciclib unless deemed appropriate by 
the invest igator.
See Secti on 6.5for addi tional guidance on concomitant therapy .
5.4. Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  but are 
not subsequently enrolled in the study .  A minimal set of screen failure informat ion is required to 
ensure transparent reporting of screen failure partici pants to meet the Consolidated Standards of 
Reporting Trials publishing requirements and to respond to queries from reg ulatory  authori ties.  
Minimal informat ion includes demography, screen failure details, eligibilit y criteria, and any 
SAE s.
The fo llowing participants may be eligible for re -screening:
Parti cipants who become eligible to enroll in the study as a result of a protocol 
amendment.
Parti cipants whose status haschanged such that the eligibilit y criterion that caused the 
participant to screen fail would no longer cause the participant to fail screening again 
(e.g., unexpected surgery  during the screening period that is no l onger rel evant 
following recovery  from surgery).
A patient who complete sscreening and meet sall inclusion and exclusio n requirements 
but is unable to be enro lled due to extenuat ing circumstances (such as severe weather, 
death in family , child illness).
The interval between rescreening should be ≥2 weeks.  Individuals may  be rescreened a 
maximum o f 2times.  The individual must sign a new ICF and will be assigned a new 
ident ificat ion number.  
Repeat ing laboratory  testi ng during the screening pe riod or repeating screening tests to comply  
with the protocol  designated screening period does not constitute rescreening .
CONFIDENTIAL I3Y-MC-JPCY (b)
386. Study Intervention
Study  intervent ion is defined as an y invest igational intervent ion(s), m arketed product(s), 
placebo ,or medical device (s)intended to be administered to a study  parti cipan taccording to the 
study  protocol .  In CYCLONE 1, study intervent ion is defined as the administration of
abemaciclib .
6.1. Study Intervention (s) Administered
Abemaciclib will be administered at a starting dose of 200 m gorally twicedaily  witha minimum 
of 6 hours between doses, at approximately  the same time every day. Abemaciclib shoul d be 
swallowed who le wit h a gl ass of water (do not chew, crush, split, disso lve in water, or alter in 
any way prior to swallowing). Abemaciclib may be taken with or without food.
If aparticipant misses a dos e at the scheduled t imefornonmedical re asons ,the dose shoul d be 
taken as soon as possible on the sam e day  and then twice -daily administration shoul d be resumed
(with at least 6 hours separating doses).   Ifaparticipant vomit s after taking a dose , then the dose 
shoul d not be retaken andthenext dose shoul d be taken at the usual scheduled time.
The invest igator or his/her designee is responsible for the fo llowing:
Explaining the correct use of the drug and planned duration of each individual’s 
treatm ent to the participant /study -site personnel/legal representative.
Verifying the instructions are fo llowed properly .
Maintaining accurate records of abemaciclib dispensing and co llection.
Returning all unused medicat ion to Lilly, or its designee at the end of the study , 
unless the site is a uthorized by Lilly  or its desi gnee to destroy  unused medicat ion, 
as allowed by  local law.
Study Intervention Dose Treatment Schedule Route of Administration
Abemaciclib 200 m g Twice daily Oral
6.2. Preparation/Handling/Storage/Accountability
The invest igator or designee must confirm appropriate temperature /storage conditions have been 
maintained during transit for all study  intervent ion received and any discrepancies are reported 
and reso lved before use of the study  intervent ion. 
Only participant s enro lled in the study  may receive study  intervent ion and only authorized study  
personnel may supply  study  intervent ion. All study intervent ion must be stored in a secure, 
environmentally  controlled, and m onitored (m anual  or autom ated) area i n accordance with the 
labeled storage condit ions with access limited to th e invest igator and authorized study  personnel . 
The invest igator ,or authori zed study  personnel , is responsible for study  interventi on 
accountabilit y, reconciliat ion, and record maintenance (that is, receipt, reconciliat ion, and final 
disposi tion records). 
CONFIDENTIAL I3Y-MC-JPCY (b)
39Further gui dance and information for the final disposit ion of unused study  interventi ons are 
provi ded in the Pharmacy Manual.
6.2.1. Selection and Timing of Doses
A treatm entcycle is defined as an interval of 28 days. Abemaciclib will be administered orally 
twice daily  at approximately  the same t imes each day on Days 1 through 28 of a 28- day cycle 
(±3 days). Details on treatment administration are described in Section 6.1.In the event of a 
dose suspensio n due to toxicit y immediately prior to the beginning of a cycle, the PK sampling 
schedule outlined in Section 1.3.1 may require adjustment and the sponsor should be notified. 
A cycle delay  or earlier start due to logist ical reasons (for example, due to holiday , weekend, 
inclement weather, or other unforese en circumstances), will be permitted for up to a maximum o f 
7 day s (and not be considered a protocol vio lation). Inexcept ional cases, such as planned del ays 
(including but not limited to vacat ion or holidays), addit ional study  treatm ent may  be dispensed
after di scussio n with Lilly CRP/CRS .    
Parti cipants may continue to receive study  intervent ionuntil evidence of disease progression ,or 
any discont inuat ion criteria are m et (See Section 7). 
6.3. Measures to Minimize Bias: Randomization and Blinding
This is a non -rando mized, open -labelstudy . 
6.4. Study Intervention Compliance
Parti cipant compliance wit h study  intervent ionwill be asse ssed at each cycle .  Com pliance will 
be assessed by  count ing returned tablets.   Study  medi cation administrati on data will be recorded 
in the participant ’s medical record and eCRF. Deviat ion(s) from the prescribed dosage regimen 
shoul d be recorded in the eCRF .
Parti cipants who are significant ly nonco mpliant will be discont inued fro m the study  after 
discussio n with Lilly CRP/CRS. A participant will be considered significant ly nonco mpliant if 
he missed more than 7 consecut ive days o f study  medicat ion (full dose) or more than 25% 
cumulative days of study medicat ion (full dose). Similarly, a participant may be considered 
significant ly noncom plian t if heis judged by the investigator to have intent ionally  or repeatedly 
taken more than the prescribed amount of medicat ion. Abemaciclib dose suspensio ns or delays 
related to toxi city may occur and will not result in a participant being considered nonco mpliant.
6.5. Concomitant Therapy
Appropriate documentation for all forms of premedicat ions, supportive care, and concomitant 
medicat ionsincluding over-the-counter and analgesics use must be recorded in the eCRF . 
Concomitant medicat ions and supportive care th erapies must also be documented at time of 
discontinuat ions and at the short -term 30-day follow-up visit. The Lilly CRP/CRS should be 
contacted if there are any quest ions regarding concomitant or prior therapy .  Refer to the 
prescribing information o f the concomitant medications for additional informat ion. 
CONFIDENTIAL I3Y-MC-JPCY (b)
40Required:
Parti cipants who have not undergone bilateral orchiectomy are required to continue ADT with a 
GnRHa throughout the study . The cho ice of theGnRH awill be at the invest igator's discretion.
Permi tted:
Bone l oss prevent ion treatment with bisphosphonates ordenosumab per their respective 
approved labels. Switch ingbetween bisphosphonates and denosumab is permitted during study
as long as it is in the absence of disease progression, and due to reasons including, but not 
limited to, tolerabilit y.
Use wi th Caut ion:
Abemaciclib is extensively metabo lized through oxidat ion by cytochro me P450 (CYP)3A. In 
clinical drug interaction studies, 
coadministration of clarithro mycin, a strong CYP3A inhibitor, increased exposure to 
abemaciclib by 3.4 -fold (Study  I3Y-MC-JPBE ),and 
coadministration of rifampin, a strong CYP3A inducer, decreased exposure to 
abemaciclib by 95% (Study I3Y-MC-JPBF).  
Strong inhibitors of CYP3A (given via non -topical routes of administration) shoul d be 
subst ituted or avoided if possible ( Secti on 10.6, Appendix 6).This includes grapefruit or 
grapefruit juice . In parti cular, avoid oral administration of the very strong CYP3A inhibitor,
ketoconazo le. The informat ion in Section 10.6, Appendix 6,is provided for guidance to 
investigators and does not preclude the use of these medicat ions if clinically indicated.  
If coadministration with a strong CYP3A inhibitor is unavo idable, investigators should reduce 
the dose of abemaciclib by 50 mg at the start of CYP3A inhibitor treatment. That is, for patients 
receiving 200mg twice daily, reduce the dose to 150mg twi ce daily . For pati ents who have 
already dose reduced to 150mg or 100 m g twice daily  for tol erabili ty, reduce the dose further to 
100mg or 50 m g twice daily , respect ively .Alternatively , the invest igator smay consi der 
suspending abemaciclib for the durati on of  the CYP3A inhibitor medicat ion.Dose suspensio ns 
≥28 days must be discussed with Lilly CRP/CRS .
Upon discont inuat ion of the strong CYP3A inhibit or, abemaciclib may be resumed at the same 
dose level or re-escalated to the dose that was used before starting the strong inhibitor after a 
sufficient washout period ( at least 3 half -lives of the strong inhibitor). Re -escalat ion of the 
abemaciclib dose requires review and approval from Lilly  CRP/CRS. Inducers of CYP3A shoul d 
be substituted or avoided if possible ( Section 10.6, Appendix 6). Coadministration with a 
CYP3A inducer ≥28 days must be discussed wit h Lilly CRP/CRS .
Transporter Substrates
At clinically relevant concentrations, abemaciclib inhibits the transporters P -glycoprotein, breast 
cancer resistance protein, organic cat ion transporter 2 (OCT2), mult idrug and toxin extrusion 
protein 1 (MATE1), and MATE2- K. The observed serum creatinine increase in clinical studies 
with abemaciclib is likely due to inhibit ion of tubular secret ion of creatinine via OCT2, MATE1, 
CONFIDENTIAL I3Y-MC-JPCY (b)
41and MATE2- K.In vivo interactions of abemaciclib with narrow therapeutic index substrates of 
these transporters, such as digoxin and dabi gatran , may occur.
Prohibited : 
With the exception of a GnRH a,no other anticancer therapy  will be permitted while participant s 
are on study interventi on(including ,but not limited to [anti-]horm onal agents , other CDK4
and/or CDK 6 inhibitors, biologics,other antineoplastic and invest igationalagents, 
chemotherapy, radiopharmaceut icals, immunotherapy ,anti-cancer vaccin es, ketoconazole ).
Palliat ive radiat ion or surgi cal intervent ion to treat symptoms result ing from metastati c disease is 
not allowed.
Drugs , or herbal /non-herbal products (e.g.,saw palmetto or pomegrana te) that have known 
prostate cancer activit y and/or are known to affect PSA l evels ,are not permitted while on study  
intervent ion. Megestrol  acetate as an appetite stimul ant is not permitted . 
6.5.1. S upportive Care
Parti cipants shoul d receive full supportive care to maximize qualit y of life.  Participants will 
receive supportive care as judged by  the treating physician.  If it is unclear whether a therapy  
shoul d be regarded as supportive care, the invest igator shoul d consul t with the Lilly CRP/CRS.  
Use of any  supportive care shoul d be recorded on the eCRF.
6.5.1.1. Supportive Management for Diarrhea
When abemaciclib is initiated, the pa rticipant should receive instructions on the management of 
diarrhea.  In the event of diarrhea, support ive measures should be init iated as early as possible .  
These include:
At the first sign o f loose stools, the participant shoul d initiate ant i-diarrheal  therapy  (e.g., 
loperamide) and notify the investigator/site for further instructions and appropriate 
follow-up.
Parti cipants should also be encouraged to drink fluids (e .g.,8 to 10 glasses of clear 
liquids per day ).
Site personnel should assess response within 24 hours.
If diarrhea does not resolve with ant idiarrheal therapy  within 24 hours to either bas eline 
or Grade 1, abemaciclib shoul d be suspended unt il diarrhea is resolved to baseline or 
Grade 1.
When abemaciclib recommences dosing should be adjusted as outlined in Secti on6.6.
If diarrhea is severe (requiring IV rehydration) and/or associated with fever or severe 
neutropeni a, broad -spectrum ant ibiotics,such as fluoroquinolones must be prescribed.
Participants with severe di arrhea or any  grade of diarrhea associated with severe nausea or 
vomiting shoul d be carefully mo nitored and given IV fluid (IV hy dration) and electrolyte 
replacement.
Refer to Section 6.6for guidance on dose adj ustments of abemaciclib for patients with diarrhea 
and see Secti on 10.7, Appendix 7 ,for diarrhea CTCAE grades .
CONFIDENTIAL I3Y-MC-JPCY (b)
426.5.1.2. Growth Factor s
Growth factors should not be administered to a pa rticipant to satisfy study  inclusio n criteria.
While o n study  treatm ent, g rowth factors may be administered in accordance with American 
Society of Clinical  Oncol ogyguidelines (Smit h et al . 2015).  Dosing of abemaciclib must be 
suspended if the administration of growth factors is required and must not be recommenced 
within 48 hours of the last dose of growth factors having been administered.  Following the 
administration of growth factors, the dose of abemaciclib must be reduced by  1dose l evel on 
recommencement, if a dose reduction for the specific event necessitat ing the use of the growth 
factors has not already occurred .
6.6. Dose Modification
Dose adjust ments (suspensio ns and reductions) will be made based on the clinical assessment of 
hematol ogic and nonhematologic toxicit ies (defined as an AE possibly related to abemaciclib per 
investigator judgment).  The CTCAE v5.0 will be used to assess AEs.  Abemaciclib may be 
suspended for a maximum o f 28 days to allow a participant sufficient time for recovery fro m 
abemaciclib -related toxici ty. If a patient does not recover fro m the toxi city within 28 days fro m 
the time o f last treatm ent, the patient should be considered for permanent discontinuation from 
abemaciclib. In exceptiona l circumstances, a delay  >28 days is permi tted upon agreem ent 
between the invest igator and the Lilly CRP/CRS.
Parti cipants undergoing non-tumor rel ated surgical procedures shoul d follow the gui delines 
below :
For minor surgeries and procedures (for example, ambulatory ), invest igators should treat 
as clinically indicated and closely  monitor any  signs of infect ion or healing 
complicat ions.
For m ajor surgeri es, the recommendat ion is to suspend dosing of abemaciclib for at least 
7 day s before surgery  and may  be resumed as clinically indicated.
Consider monitoring neutrophils and platelets befo re surgery  and before resuming 
abemaciclib. The scars should be asept ic and healing process be reasonable before 
resuming abemaciclib.
Dose reductions for abemaciclib shou ld beperformed as shown in the table bel ow.  Abemaciclib
must be reduced sequent ially by 1dose l evel, unless an excepti on is granted in consultat ion with 
the Lilly  CRP/CRS. For participants requi ring a dose reduction of study  intervent ion, any re -
escalat ion to a prior dose level is permitted only after consultat ion with and approval  bythe Lilly  
CRP/CRS.
6.6.1. Dose Reductions for Abemaciclib
Study DrugStarting 
doseDose Reduction
First Second Third Fourth
Abemaciclib200 m g 
twice daily150 m g 
twice daily100 m g 
twice daily50 m g 
twice dailyDiscontinue
CONFIDENTIAL I3Y-MC-JPCY (b)
436.6.2. Dose Adjustments and Delays Abemaciclib
The toxi city dose adjust ments and delays table below provides guidance for the management of 
treatm ent-emergent, related (i.e.,withreasonable causal relat ionship wit h abemaciclib ), and 
clinically significant AEs associ ated wi th abemaciclib .An invest igator may suspend or reduce 
doses wi thout meet ingoneof the cri teria bel ow and woul d not be considered a protocol 
deviat ion.
Toxicity Dose Adjustments and Delays of Abemaciclib
Toxicity Type CTCAE Grade Dose Modification
Hematologic ToxicityGrade 1 or Grade 2 No dose modification is required
Grade 3 Suspend dose until toxicity resolves to 
≤Grade 2
Dose reduction is not required
Recurrent Grade 3 , 
or Grade 4 Suspend dose until toxicity resolves to 
≤Grade 2
Resume at next lower dose level
Hematologic Toxicity: If 
Patient Requires 
Administration of Blood Cell 
Growth Factors
Additional guidance for use of 
growth factors is in Section 
6.5.1.2Regardless of severity
(Use of growth factors 
according to ASCO Guidelines)Suspend dose for at least 48 hours after the 
last dose of blood cell growth factor and 
until toxicity resolves to ≤Grade 2
Resume at next lower dose unless the dose 
was already reduced for the toxicity that led 
to the use of the growth factor
Non-hematologic Toxicity
Excluding Diarrhea, ALT/AST 
Increased , and Interstitial Lung 
Disease/Pneumonitis (see 
below)
Additional guidance for renal 
monitoring is in Section 8.2.2.2
and for venous thromboembolic 
events is in Section 8.2.2.3Grade 1 or Grade 2 No dos e modification is required
Persistent or recurrent Grade 2 
that does not resolve with 
maximal supportive measures 
within 7 days to baseline or 
Grade 1 .
Grade 3 or Grade 4Suspend dose until toxicity resolves to 
baseline or Grade 1
Resume at next lower dose level
Diarrhea
Additional guidance for diarrhea 
management is in Section 6.5.1.1 . 
See Section 10.7, Appendix 7 ,for 
CTCAE 5.0 gradingGrade 1 No dose modification is required
Grade 2 that does not resolve 
within 24 hours to ≤Grade 1Suspend dose until toxicity resolves to 
≤Grade 1
Dose reduction is not required
Grade 2 that persists or recurs 
after resuming the same dose 
despite maximal supportive 
measures .Suspend dose until toxicity resolves to 
≤Grade 1
Resume at next lower dose level
CONFIDENTIAL I3Y-MC-JPCY (b)
44Toxicity Type CTCAE Grade Dose Modification
Grade 3,or Grade 4 , or requires 
hospitalization
ALT/AST Increased
See Section 8.2.2.1 for additional 
guidance for hepatic monitoring 
andSection 8.2.2.1.1 forspecial 
hepatic safety data collection . See 
Section 10.7, Appendix 7 ,for 
CTCAE 5.0 gradingGrade 1 or Grade 2 No dose modification is required
Persistent or recurrent Grade 2 ,
or Grade 3Suspend dose until toxicity resolves to 
baseline or Grade 1
Resume at next lower dose
≥Grade 2 with total bilirubin
>2× ULN, in the absence of 
cholestasis ,
or Grade 4Discontinue abemaciclib
Interstitial Lung 
Disease/Pneumonitis
Additional guidance for 
ILD/ pneumonitis monitoring is in 
Section 8.2.2.4 . See Section 10.7, 
Appendix 7 ,for CTCAE 5.0 
gradingGrade 1 or Grade 2 No dose modification is required
Grade 2 that persists or recurs 
despite maximal supportive 
measures and does not return to 
baseline or Grade 1 within 7 
days.Suspend dose until toxicity resolves to 
baseline or Grade ≤1
Resume at next lower dose level
Grade 3 or Grade 4 Discontinue abemaciclib
Abbreviation s: ALT = alanine aminotransferase ; ASCO = American Society of Clinical Oncology ; AST = aspartate 
aminotransferase; CTCAE = Common Terminology Criteria for Adverse Events (NCI 2017) ;ILD =interstitial 
lung disease; ULN = upper limit of normal .
Note: Determination of persistent events will be at the discretion of the investigator. Recurrent toxicity refers to the 
same event occurring within the next 8 weeks (as measured from the stop date of the first event. As a general 
guidance, based on the risk/benefit balance assessment per the investigator , for a participant who experiences a new 
episode of Grade 3 hematological toxicity after more than 8 weeks following the last episode of the same G rade 3 
hematological toxicity, the investigator may consider resuming the participant on the same drug dose should the 
participant satisfy the following conditions:
The participant showed stable hematological counts (Grade ≤2) during that timeframe
In the absence of any infectious sign or risk factor
The participant is benefiting from study intervention .
6.7. Intervention after the End of the Study
Please refer to the study  schema (Secti on 1.2) for a depi ction of study  com pletion, continued 
access period, and the end of study .
6.7.1. Study Completion
Study  com pletion will occur fo llowing the final analysis of all primary and secondary object ives 
(Secti on 4.4), as determined by Lilly.  Invest igators will cont inue to fo llow the SoA (Section 1.3)
for all participants untilnotified by Lilly  that study com pletion has occurred.
CONFIDENTIAL I3Y-MC-JPCY (b)
456.7.2. Continued Access
Parti cipants who are still on study  intervent ion at the time o f study  com pletion may cont inue to 
receive study  intervent ion if they are experiencing clinical benefit and no undue risks.
The continued access period will apply  to this study  only if at least 1 parti cipant is still on study  
intervent ion when study  com pletion occurs.   Lilly will notify investigators when the continued 
access period begins.
Parti cipants are not requi red to si gn a new ICF before treatment is provided during the continued 
access period; the init ial ICF for this study  includes continued access under this protocol.
The parti cipant’s cont inued access to study intervent ion will end when a criterion for 
discontinuat ion is met (Section 7).  Conti nued access fo llow-up will begin when the participant 
and the invest igator agree to di scont inue study  intervent ion and lasts approximately 30days.  
Follow-up procedures will be performed as shown in the Cont inued Access SoA.
Parti cipants who are in short -term follow-up when the continued access period begins will 
continue in short -term follow-up unt il the 30-day short -term follow-up visit is completed. Long -
term follow-up does not apply.
Parti cipants who are in l ong-term follow-up when the continued access period begins will be 
discontinued fro m long-term follow-up.
In all cases, no fo llow-up procedures will be performed for a participant who withdraws 
informed consent unl ess he or she has explicit ly provided permissio n and consent.
CONFIDENTIAL I3Y-MC-JPCY (b)
467. Discontinuation of Study Intervention and Participant
Discontinuation/Withdrawal
7.1. Discontinuation ofStudy Intervention
Parti cipants may discontinue the study  intervent ionat any  time for any  reason. Invest igators 
shoul d try to find out the reason and document it on the corresponding CRF .
The reason and date of discont inuat ion will be co llected for all participants .
Parti cipants wi th PSA -only progression should continue study  intervent ion unt il disease 
progression (radiographic and/or symptomat ic progressio n), when participant safet y is not 
compromised. 
Study  intervent ionshoul d be cont inued for as long as the participant consents and co mplies wit h 
study  procedures and requirements, is tolerat ing the study intervent ion, unt il radiographic
progression according to RECIST 1.1 for soft ti ssue and/or PCWG 3 for bone; and/or until 
symptom atic progression .
Symptomatic progression is defined as:
Symptom atic Skel etal Event (SSE), defined as symptom atic fracture, surgery  
or radi ation to bone, or spinal cord compressio n
Pain progressi onor worsening of disease -related symptom s requi ring 
initiation of a new systemic anti-cancer therapy .
Development of clinically significant symptoms due to loco -regional tumor 
progression requiring surgical intervent ion or radiation therapy .
When study  intervent ion is discont inued due to symptomat ic progression, the investigator should 
obtain CT/MRI and bone scan imaging within 14 days to assess for radiographic progression, 
prior to the participant initiating radiotherapy ,surgery or subsequent anti -cancer therap y
(whichever comes first) .
Patients discont inuing study  intervent ion due to documented radiographic progression will be 
followed for the development of symptomatic progressio n until start of new ant icancer therapy, 
withdrawal  of consent, death, or study  com pletion, whichever occurs first.
Participants discontinuing study  intervent ion prior to documented radiographic progression will 
continue to have scheduled disease assessments until documented radiographic progression, start 
of new ant icancer therapy , withdrawal  of consent, death, or study  com pletion, whichever occurs 
first.
All participants discontinuing study  intervent ion will  have procedures performed as shown in 
Secti on 1.3andenter the short -and-long-term follow-up periods and will be fo llowed for the 
initiation of subsequent ant i-cancer therapies and survival status every 3 months until death, loss 
of follow-up, or wi thdrawal of consent, whichever com es first.  
Parti cipants willbediscont inued from study  intervent ionin the fo llowing ci rcumstances :
CONFIDENTIAL I3Y-MC-JPCY (b)
47the participant or the participant ’s desi gnee (f or exam ple, parents or l egal guardian) 
requests to be discont inued from study  interventi on
sponsor decisio n
investi gator deci sion
the participant is enrolled in any other clinical trial invo lving an invest igational product 
or other ty pe of  medical research judged not to be scientifically or medically  com patible 
with this study
radiographic or symptomatic d isease progressi onas discussed above 
the participant , for any  reason, requi res treatm ent from  another therapeutic agent that has 
been demo nstrated to be effective for treatment of the study  indicati on.  Di scont inuat ion 
from study  intervent ionwill occur pri or to introducti on of  the new agent .
the participan texperiences unacceptable toxicit y
the participant is significant lynonco mpliant with study  procedures and/or intervent ion.
In exceptional circumstances, aparticipant m aycontinue study  intervent ionbeyond disease 
progression if there is no effect ive alternat ive therapy and the participant, in the opinio n of the 
investigator, is receiving clinical benefit from the study  drug .  In these rare cases, the investigator 
must obtain documented approval fro mthe Lilly  CRP/CRS to allow the patient to conti nue study  
intervent ion.Addit ionally , the pati ent m ust reconsent prior to continuing to receive study  
intervent ion.
7.2. Participant Discontinuation /Withdrawal from the Study
A participant will be discont inued fro m the study  in the foll owing c ircumstances: 
participat ion in the study needs to be stopped for medical, safet y, regul atory , or other 
reasons consistent with applicable laws, regulations, and good clinical pract ice (GCP)
at any  time at the participant ’sown request 
at the request of the participant ’sdesignee (for example, parents or legal guardian)
at the discretion of the invest igator 
At the time of discont inuing from the study , if possible, an early discont inuat ion visit should be 
conducted, as shown in the S oA (Secti on 1.3). Theparticipant will be permanent ly discont inued 
both fro m the study  intervent ionand from  the study  at that tim e.
7.2.1. Discontinuation of Inadverte ntly Enrolled Pa rticipant s
The cri teria for enrollment m ust be fo llowed explici tly.  If an inadvertent ly enro lledparticipant i s 
ident ified, the sponsor and invest igator must be notified.  A discussio n must occur between the 
Lilly CRP/CRS and the invest igator to determine if the pat ient may cont inue in the study , with or 
without study  drug. Inadvertent ly enro lled patients may continue in the study and on study drug 
when the Lilly  CRP/CRS agrees with the invest igator that it is medically appropriate for that 
patient to do so. The patient may not continue in the study  with or wi thout study dru g if the Lilly 
CRP/CRS does not agree with the invest igator’s determination that it is medically appropriate for 
the pati ent to conti nue. The invest igator must ob tain documented approval from the Lilly 
CRP/CRS to allow the inadvertent ly enro lled patient t o continue in the study  with or wi thout 
study  drug.  Pati ents who are di scont inued fro m the study  will have fo llow-up procedures 
CONFIDENTIAL I3Y-MC-JPCY (b)
48perform ed as outlined in Sect ion 1.3(Sched ule of Act ivities), Section 8.2(Safet y Assessments), 
and Sect ion 8.3(Adverse Events and Serious Adverse Events) of the protocol. 
7.3. Lost to Follow up
A participant will be considered lost to follow -up if he repeatedly  fails to return for scheduled 
visits and is unable to be con tacted by  the study  site.Site personnel or des ignee are expected to 
make diligent attempts to contact participants who fail to return for a scheduled visit or were 
otherwi se unable to be fo llowed up by the site.
Site personnel, or an independent third party , will  attem pt to collect the vital status of the 
participant within legal and ethical boundaries for all participants who init iate treatm ent.Public 
sources may  be searched for vi tal status i nformat ion.If vital status is determined to be deceased , 
this will be docum ented ,and the participant will not be considered lost to fo llow-up. Lilly 
personnel will not be invo lved in any attempts t o collect vital status information.
CONFIDENTIAL I3Y-MC-JPCY (b)
498. Study Assessments and Procedures
Study  procedures and their timing are summari zed in the SoA (Section 1.3).Protocol waivers or 
exempt ions are not allowed. Immediate safet y concerns should be discussed with the sponsor 
immediately  upon occurrence or awareness to determine if the participant shoul d cont inue or 
discontinue study  interventi on.
Adherence to the study  design requi rements, including those specified in the SoA, is essent ial 
and required for study  conduct .
All screening evaluat ions must be com pleted and reviewed to confirm that potential participants 
meet all eligibilit y criteria. The invest igator maymaintain a screening log to record details o f all 
participants screened and to confirm eligibilit y or record reasons for screening failure, as 
applicable.
Appendix 2 (Secti on10.2) provides a list of laboratory  tests that will be performed for this study .
The SoA (Section 1.3)provides the schedule for collect ion of samples in this study .Unless 
otherwi se stated in the following subsect ions, all samples collected for specified laboratory  tests 
will be destroy ed wi thin 60 days after receipt of confirmed test results. Certain samples may be 
retained for a longer period, if necessary , to com ply with applicable laws, regulat ions, or 
laboratory  certificati on standards .
8.1. Efficacy Assessments
Baseline and on -study  tumor assessments will be performed for each participant as per the S oA 
(Secti on 1.3),according to the calendar days, regardl ess of intervent ion delays.  During the
study , unscheduled tumor assessment and appropriate imaging should be considered if there are 
signs or symptom s suggestive of disease progression.
All applicable imaging will be done locally.  All CT/MRI and bone scan i mages will be collected 
and stored centrally. 
The CT portion of a positron emission tomography (PET) -CT scan may be used as a method of 
response as sessment if the site can document that the CT is o f ident ical diagnostic qualit y to a 
diagnosti c CT (wi th IVand oral contrast). A PET scan alone or as part of a PET -CT may be 
perform ed for addi tional analyses but cannot be used to assess response accordi ng to 
RECIST 1.1.
The m ethod of assessment used at baseline must be used consistent ly for seri al tum or assessment 
throughout the study .
For participants continuing treatment during the Continued Access Period (after study  
completion), efficacy  assessments (frequency  and type of assessments) will be at the discret ion 
of the invest igator.
8.1.1. Definitions of Efficacy Measures
Objective Response Rate is defined as the proportion of participants who have a soft tissue best 
overall response of completeresponse ( CR)or partial response ( PR)per RECIST 1.1, and do not 
have concurrent bone disease progression per PCWG3, as assessed by the invest igator/local 
CONFIDENTIAL I3Y-MC-JPCY (b)
50radiologist. The primary analysis will require confirmation o f responses, but interim analyses 
will consider both confirmed and unconfirmed responses .
Radiographic Progression Free Survival
The consensus guidelines of RECIST 1.1 and PCWG3 have been taken into considerat ion for the 
determinat ion of ra diographic disease progression.
For all pa rticipants , imaging studies (radionuclide bone scan and CT or MRI scan of the chest, 
abdo men, and pelvis) will be performed locally at baseline and repeated within 7 days prior to
Day 1of every  second cycle (every 8 weeks) beginning with Cycle 3 and continuing until 
radiographic progression, and wi thin 14 days of symptom atic progression if no radiographic 
progression yet per the SoA (Section 1.3).
Radiographic PFS ( rPFS )will be assessed by sequent ial imaging studies and is defined as the 
time fro m the date of treatm ent ini tiationto the earliest date of invest igator -determined 
radiographic di sease progressi on by  object ive radiographic CT/MRI disease assessment per 
RECIST 1.1 for soft tissue AND/OR radionuclide bone scan using the PCWG3 cri teria for bone 
or death from any  cause, in the absence o f docum ented disease progression .Censoring rules are 
described in detail in the Statistical Analysis Plan ( SAP).  Radiographic disease progression in 
soft tissue does not require a confirmatory  scan.
The documentation required for the determ ination of radiographic disease progression in bone 
per PCWG3 is listed in the text below and in the following table.
Bone Progression per PCWG3
A participant is considered to have progressed by bone scan if :
1. For radi ographic di sease progressi on on bone observed onthe first post -treatm ent bone 
scan
- Appearance of at least 2 new lesio ns on the first post -treatm ent scan (Week 9), with at 
least 2 additional lesions on the next scan (Week 17; 2+2 rule) .
-The date of progression is the date of the fi rst post -treatment scan, when the first 2 new 
lesions were docum ented.
OR
2. For radiographic disease progression in bone observed after the first post -treatment bone 
scan (Week 17 or later) :
- Appearance of at least 2 new lesio ns relative to the first post-treatment scan (Week 9 , 
new baseline ) that are persi sting on a confirmatory subsequent scan (at least 6 weeks 
later or at the next scheduled assessment).
-The d ate of progression is the date of the scan that first documents the second lesio n.
Changes in int ensity of uptake al one do not const itute ei ther progressi on or regressi on.
CONFIDENTIAL I3Y-MC-JPCY (b)
51Date Progression 
DetectedCriteria for 
ProgressionCriteria for 
Confirmation or 
Progression 
(Requirement and 
Timing)Criteria for 
Documentation of 
Disease Progression 
on Subsequent Scan
Week 9 (C3D1)
(or earlier 
unscheduled visit)Two or more new 
lesions com pared to 
baseline bone scanRequi res confirmati on 
at least 6 weeks after 
progression ident ified 
or at the Week 17 
assessmentConfirmatory  scan:  
Two or more new 
bone l esions 
compared to Week 9 
scan
Week 17 or l aterTwo or more new 
lesions on bone scan 
compared to Week 9 
bone scanRequi res confirmati on 
at least 6 weeks after 
progression ident ified 
or at the next 
scheduled assessmentConfirmatory  scan:  
Two or more 
persisting (i.e., also 
present on the prior 
scan) new lesio ns 
relative to Week 9 
scan
Abbreviations:  C = cycle; D = day .
Source:  Scher et al .2016 .
Overall Survival is defined as the time fro m the date of treatm ent init iationto date of death due 
to any  cause.   For participants not known to have died at the time of analysis, OS will be 
censored at the last known alive date.
Duration of Response is defined as the time fro m first docum ented evidence of soft tissue CR or 
PR until earliest date of disease progression by objective radiographic disease assessment per 
RECIST 1.1 for soft tissue AND/OR radionuclide bone scan using PCWG3 criteria for bone as 
assessed by  the invest igator/local radio logist, or death from  any cause, whiche ver occurs first.
Disease Control Rate is defined as the proportion of patients who have a soft tissue best overall 
response of CR, PR, or stable disease ( SD)per RECIST 1.1, and do not have concurrent bone 
disease progressi on per PCWG3.
Time to PSA progre ssion isdefined as the time from the date of treatm ent ini tiation to the date 
of first observation o f PSA progressi on.  The PSA progression is defined as a ≥25% increase and 
an abso lute increase of ≥2 ng/mL above the nadir (or baseline value if baseline is the smallest on 
study ), which is confirmed by a second value obtained 3 or more weeks later.  Any post -baseline 
PSA m easurements wi thin 12 weeks since baseline will be ignored in determining PSA
progression (Scher et al. 2016) .
Time to Symptomatic Progr ession is defined as the time fro m the date of treatment init iationto 
any of the fo llowing (whichev er occurs earlier):
Symptom atic Skel etal Event (SSE ),defined as symptomat ic pathol ogical fracture, tumor-
related orthopedi c surgery ,or external beam radia tion to bone progression , or spinal cord 
compressi on.
Pain progression or worsening of disease -related symptom s requi ring ini tiation of a new 
systemic anti -cancer therapy .
CONFIDENTIAL I3Y-MC-JPCY (b)
52Development of clinically significant symptoms due to loco -regional tumor progressi on 
requi ring surgical intervent ionor radiati on therapy .
Prostate Specific Antigen Response Rate is defined as the proportion of participants with a 
reducti on in PSA level of ≥50% from  baseline (see Secti on 9.4.1 ), confirmed with a second 
assessment conducted at least 3 weeks later.
PSA Change from Baseline to 13 Weeks is defined as the individual proportion of rise or fall in 
PSA at 13 weeks relative to baseline (see Sect ion 9.4.4 ).  Missing observat ions will not be 
imputed.
Maximum Decline in PSA is defined as the relative change in PSA fro m baseline (see Section 
9.4.1 ) to the lowest on -study  value, occurring at any  time po int.
8.1.2. Appropriateness of Assessments
The m easures used to assess safet y and efficacy in this study  are consistent wi th those used in 
most convent ional onco logy studies. 
8.2. Safety Assessments
Planned time po ints for all safet y assessments are provided in the SoA (Sectio n1.3).For each 
participant , vital signs, l aboratory  tests, and other test sshoul d be co llected as shown in the SoA.
Any clinically  significant findings that result in a diagnosis and that occur a fter the participant
receives the first dose of study  intervent ionshoul d be reported to Lilly or its designee as an AE 
via eCRF.
Addit ional information regarding guidance for monitoring of hepat ic function, renal functi on, 
venous thromboembolic events ( VTE), and interstiti al lung disease ( ILD) /pneumo nitis can be 
found in Section 8.2.2 .
8.2.1. Clinical Safety Laboratory Assessments
Lilly or i ts desi gnee will  provide the investi gator wi th the resul ts of safety  laboratory  tests 
analy zedby a central vendor, if a central  vendor i s used for the clinical trial.   
See Secti on 10.2,Appendix 2 ,for the list of clinical laboratory  tests to be performed and to the 
SoA (Section 1.3)for the timing and frequency.
The invest igator must review laboratory resul ts, docum ent this review, and report any clinically 
relevant changes occurring during the study  as an AE.The laboratory  reports m ust be filed with 
the source documents .  Clinically significant abnormal laboratory findings are those which are 
not associ ated wi th the underlying disease, unless judged by  the invest igator to be more severe 
than expected for the participant's condit ion.
All laboratory  tests wi th values considered clinically  significantly abnorm al during parti cipat ion 
in the study  or until the co mpletion of Visit 801 shoul d be repeated until the values return to 
norm al or baseline or are no l onger considered clinically significant by  the investi gator or 
medical mo nitor.
oIf such values do not return to normal/baseline wit hin a peri od of  time judged reasonable 
by the investigator, the etio logy should be identified ,and the sponsor notified.
CONFIDENTIAL I3Y-MC-JPCY (b)
53oAll protocol -requi red laboratory  assessments, as defined in Section 10.2, Appendix 2, 
must be conducted in accordance wit hthelaboratory  manual SoA.
oIf laboratory  values fro m non-protocol -specified laboratory  assessments performed at an 
investigator -designated local laboratory requi re a change in part icipant management or 
are considered clinically  significant by  the invest igator (e .g., SAE ,AE,or dose 
modificati on), then the resul ts shoul d be reported as a diagnosis ofan AE(for example, 
hypertensio n, neutropenia, etc.) .
8.2.2. Safety Monitoring
Lilly will periodically  review evolving aggregate safet y data wi thin the study  by appropri ate 
methods. 
8.2.2.1. Hepatic Safety Monitoring
Liver testing ( Secti on 10.5, Appendix 5), incl uding alanine aminotransferase ( ALT ), aspartate 
aminotransferase ( AST ), alkaline phosphatase , total bilirubin ( TBL ), direct bilirubin , gamma-
glutamyl  transferase , and creatine phosphokinase , shoul d be repeated wi thin 2 to 4 days to 
confirm the abnormalit y and to determine if it is increasing or decreasing, if one or more of these 
condi tions occur:
If a participant with baseline results of ... develops the following elevations:
ALT or AST <1.5× ULNALT or AST ≥5×ULN or
ALT or AST ≥3×ULN concurrent with TBL 
≥2×ULN
ALT or AST ≥1.5× ULNALT or AST ≥3×baseline or
ALT or AST ≥2×baseline concurrent with TBL 
≥2×ULN
Abbreviations:  ALT = alanine aminotransferase ; AST = aspartate aminotransferase; TBL = total bilirubin; 
ULN =upper limit of normal.
If the abnormalit y persists or worsens, clinical and laboratory  monitoring and evaluat ion for 
possible causes of abnormal liver tests, should be init iated by  the invest igator in consultat ion 
with the Lilly -designated m edical m onitor.  At a minimum , this evaluati on shoul d include 
physical examinat ion and a thorough medical history , including symptoms, recent illnesses (for 
example, heart failure, systemic infection, hypotension, or seizures), history  of concomi tant 
medicat ions (including over -the-counter, herbal and dietary  supplements, history  of alcoho l 
drinking and other substance abuse).  In addit ion, the evaluat ion shoul d include a blood test for 
prothrombin t ime-internat ional norm alized rati o; serol ogical tests for vi ral hepat itis A, B, C, E, 
autoimmune hepat itis; and an abdo minal imaging study  (for exam ple, ul trasound or CT scan). 
Based on the participant ’s history  and i nitial evaluation results, further testing should be 
considered, in consultation wit h the Lilly designated medical mo nitor, including tests for 
hepat itis D virus, cytomegalo virus, Epstein- Barr virus, acetaminophen levels, acetaminophen 
protein adducts, uri ne toxi cology screen, Wilson’s disease, blood alcoho l levels, urinary  ethyl  
glucuronide, and serum phosphat idylethano l.  Based on the circumstances and the invest igator’s 
assessment of the participant’s clinical condit ion, the invest igator should consider referring the 
CONFIDENTIAL I3Y-MC-JPCY (b)
54participant for a hepatologist or gastroenterologist consultation, magnetic resonance 
cholangiopancreatography , endoscopi c retrograde chol angiopancreatography , cardi ac 
echocardiogram, and/or a liver biopsy.  
8.2.2.1.1. Special Hepatic Safety Data Collection
Addit ional safet y data should be co llected via the eCRF if 1or more of the fo llowing condi tions 
occur:
In participants with baseline ALT or AST <1.5 ULN
Elevat ion of serum ALT or AST to ≥5× ULN on 2 or more consecutive blood tests
The combinat ion of  elevated ALT or AST ≥3× ULN and elevated TBL ≥2× ULN
In participants enrolled with baseline ALT or AST ≥1.5× ULN
Elevated ALT or AST ≥3× baseline on 2 or more consecut ive tests
The combinat ion of elevated ALT or AST ≥2× baseline and elevated TBL ≥2× ULN
In all study participants
discontinuat ion from study  intervent iondue to a hepatic event or abnormalit y of liver 
tests
occurrence of a hepat ic event considered to be a nSAE
8.2.2.2. Guidance for Monitoring Renal Function
Abemaciclib has been shown to increase serum creatinine due to inhibit ion of renal tubular 
transporters without affecting glo merular functi on(as m easured by  iohexol clearance). In clinical 
studi es, increases in serum creat inine occurred within the first month of abe maciclib dosing , 
remained elevated but stable through the treatment period, were reversible upon treatment 
discontinuat ion, and were not accompanied by changes in markers of renal funct ion,such as 
blood urea nitrogen, cy statin C, or calculated glomerular filtration rate ( GFR )based on cystatin 
C.
Dose adjust ment (omissio n, reducti on, or discont inuation) should not solely be based on 
interpretati on of  serum  creat inine values because these may not reflect renal function. Other 
measures of renal funct ion,such as cystatin C GFR ,shoul d be used as an alternat ive to either 
creatinine or creatinine calculat ions of GFR. A serum cystatin C is collected with the central 
chemistry  laboratory  sample . If deteri oration of  renal funct ion is suspected per the invest igator ’s 
clinical assessment, dose alteration should fo llow the protocol guidance for non -hematol ogical 
toxicities in Sect ion 6.6.2 .
8.2.2.3. Guidance for Venous Thromboembolic Events
In breast cancer ,VTE has been ident ified as an adverse drug reaction for abemaciclib in 
combinat ion with endocrine therapy (ET) . In the rando mized P hase 3 studies in participants with 
breast cancer who received abemaciclib in combination with ET,a greater number of participants
experienced VTEs in the abemaciclib plus ETarmsthan in the placebo pl us ETarmor ET al one 
arm.The m ajority of participants who experienced VTEs were treated with ant icoagulants. In 
studi es wi th single -agent abemaciclib use in the metastati c breast cancer popul ation or other 
tumor types, incl uding non-small cell lung c ancer ,no increased rates of VTEs were observed as 
CONFIDENTIAL I3Y-MC-JPCY (b)
55compared to the incidence of VTEs for these particular patient populat ions who were treated 
with other ant icancer agents. At this time, the mechanism underlying the associat ion between 
abemaciclib and the occurrence of VTEs is not known.  
Moni tor participants for signs and symptom s of deep vein thro mbosis and pulmo nary embo lism 
and treat as medically appropriate. Dose modificat ions and management should fo llow the 
protocol  guidance for non -hematol ogical  toxicities in Sect ion 6.6.2 .
8.2.2.4. Guidance for Interstitial Lung Disease/Pneumonitis
Intersti tial lung disease (ILD) /pneumo nitis has been identified as an adverse drug reaction for 
abemaciclib. The majorit y of events observed in clinical trials were Grade 1 or Grade 2 with 
serious cases and fatal  events reported. Addit ional inform ation is available in the IB.
Ask y our participants to report any  new or worsening pulmo nary symptom s,such as dyspnea,
cough, andfever, and investigate and treat as per your local clinical pract ice (including 
corticosteroi ds as appropriate ).If ILD/pneumo nitis is suspected, invest igations may include 
imaging ,such as high -resolution CT,bronchoalveolar lavage, and biopsy as clinically indicated.
Refer to Section 6.6.2 for guidance on dose adjustments of abemaciclib for patients with 
ILD/pneumo nitis (see Section 10.7, Appendix 7 ,for ILD/pneumonit is CTCAE grades) .
Discontinue abemaciclib in cases of severe (Grade 3 or 4) ILD/pneumo nitis.
8.2.3. Safety Surveillance
The sponsor has robust safet y surveillance processes based on recommendat ion made by Council 
for Internati onal Organizat ions of Medical Sciences (CIOMS )Working Group VI -Management 
of Safety Inform ation from Clinical Trials Report.  These processes are i n line wit h FDA’s 
expectati ons for Safet y Assessment Committees and theEuropean Medical Agency  (EMA )
expectati ons for m onitoring safet y in clinical trials. 
Each invest igational drug has a Developmental Safety  Surveillance Team (DSST) which is 
responsible for monitoring the safet y of participants and overseeing the evo lving safet y profile of 
investigat ional drugs. The DSST will review all available data including but not limited to 
clinical trial data (cumulat ive AE and SAE data and laboratory  data), non -clinical data 
(toxicology  studi es), epi demi ology studi es and li terature. The team will conduct real time 
review of all SAEs and other inco ming expedited safet y reports. The DSST is also responsible 
for review of accumulat ing safet y data across all trials for the invest igational drug. The DSST 
will meet in a timely  manner at pre -defined intervals or on an ad -hoc basis as r equired.
The DSST is a mult idisci plinary team  which includes a physician/scient ist who are well versed 
in Pharmacovigilance and wit h the therapeutic area for which the invest igational drug i s being 
developed. The rol es and responsibilit ies of this team an d the processes are clearly defined in 
Lilly’s internal Standard Operating Procedures .
Each invest igational drug has a Developmental Safety  Management Team  (DSMT) which is a 
cross -functional, m ultidisciplinary  team  and incl udes DSST m embers, study  team  physicians and 
other m embers depending on the necessit y such as epidemio logist, clinical pharmacologist, 
toxicologist, statist ician.  The DSST and DSMT work together to review clinical data fro m the 
clinical trial. 
CONFIDENTIAL I3Y-MC-JPCY (b)
56The DSST can make reco mmendat ions to the DSMT in order to minimize risk to participants in 
clinical trials. Such recommendations will include (but are not limited to) changes to conduct of 
the trial, determinat ion of new adverse drug reactions and determining if event(s) meets the 
criteria for exp edited reporting to regulators (such as investigational new drug [IND]safet y 
reports) and invest igators.
In addit ion, each individual clinical trial study  team  has clearly  defined processes to review all 
relevant safet y data at cohort level and trial leve l in order to monitor safet y of participants in 
clinical trials and enable trial level decisi ons such as dose escalat ion. More information about 
these processes can be found in Section 6.6of the protocol . 
Lilly Glo bal PatientSafet y has a robust process, for expedited communicat ion of SAEs and 
suspected unexpected serious adverse reactions ( SUSARs )per regulatory  requi rements and other 
important study  informat ion as needed. The protocol gives detailed information to study  sites for 
collect ion and reporting of AEs and SAE s(see Secti ons8.3and 10.3,Appendix 3). 
8.3. Adverse Events and Serious Adverse Events
Lilly standards for reporting AEs a re to be fo llowed regardl ess if country  regulatory  
requi rements are l ess stringent. A clinical study AE is any untoward medical event associated 
with the use of a drug in humans, irrespect ive if the AE i s considered related to abemaciclib .
Adverse events will be reported by  the parti cipant (or, when appropri ate, by  a caregiver, 
surrogate, or the participant's legally authorized representative).
The invest igator and any qualified designees are responsible for detecting, documenting, and 
recording events th at meet the definit ion of an AE or SAE and remain responsible for fo llowing 
up AEs that are serious, considered related to the study  intervent ion or study  procedures, or 
caused the participant to discont inue the study  intervent ion (see Section 7).
The invest igator will use CTCAE versio n 5.0 (NCI 2017 )to assign AE severit y grades . 
Invest igators are responsible for:
monitoring the safet y of participants in this study and for alerting Lilly or its designee
to any  event that seem s unusual , even if this event may be considered an 
unant icipated benefit to the participant
the appropriate medical care of participants during the study
docum enting their review of each l aboratory  safety report
following, through an appropriate health care option, AEs that are serious or otherwise 
medically important, considered related to study intervent ionor the study, or that caused 
the participant to discont inue study  interventionbefore complet ing the study. The 
participant shoul d be fo llowed unt il the event resolves, stabilizes with appropriate 
diagnosti c evaluat ion, or is reasonably  explained.  Frequency of follow-up evaluat ion is 
left to the di scret ion of theinvest igator .
Lack of drug effect is not an AE in clinical studies, because the purpose of the clinical study is to 
establish treatment effect .
CONFIDENTIAL I3Y-MC-JPCY (b)
57After the ICF is signed, study  site personnel will record via CRF/electronic data entry /designated 
data transmissio n methods the occurrence and nature of each participant ’s preexist ing condit ions, 
including clinically significant signs and symptoms of the disease under treatment in the study.
In addit ion, study  site personnel will record vi a CRF/electroni c data entry /designated data 
transmissio n methods any change in the preexist ing conditions and any new condit ions as AEs. 
Invest igators should record their assessment of the potential relatedness of each AE to study 
intervent ionvia CRF/electronic data entry /desi gnated data tra nsmissio n methods.
The invest igator will interpret and document whether or not an AE has a reasonable possibilit y 
of being related to study intervent ionor a study  procedure, taking into account the disease, 
concomitant treatments, or pathologies. A “reas onable possibilit y” means that there is a cause 
and effect relat ionship between the study  interventi onand/or study  procedure and the AE.
Planned surgeries and nonsurgical intervent ions should not be reported as AEs unless the 
underlying medical condit ion has worsened during the course of the study .
Study  site personnel  must report any  dose m odificati ons or treatm ent discont inuat ions that result 
from AEs to Lilly or its designee via CRF/electronic data entry /desi gnated data transmissio n 
methods, clarifying, if possible, the circumstances leading to the dose modificat ion or 
discontinuat ion of treatm ent
8.3.1. Time Period and Frequency for Collecting AE and SAE Information
All SAEs will be co llected fro m the signing of the ICF unt il participat ion in study  has ended. 
All AEswill be collected from  the si gning of the ICF until the short -term 30-day follow-up visit. 
Adverse event s that begin before the start of study  intervent ion but after signing of the ICF will 
be recorded on the Adverse Event CRF.  Although all AEs after si gning the ICF are recorded by  
the site in the CRF/electronic data entry , SAE reporti ng to the sponsor begins after the 
participant has signed the ICF and has received study drug. However, if an SAE occurs after 
signing the ICF , but pri or to receiving abemaciclib, it needs to be reported ONLY if it is 
considered reasonably  possibly  related to study  procedures. 
All SAEs will be recorded and reported to the sponsor or designee immediately and under no 
circumstance shoul d this exc eed 24 hours, as indicated in Secti on 10.3, Appendix 3. The 
investigator will submit any  updated SAE data to the sponsor within 24 hours of it being
available. Serious adverse events, including death, caused by disease progression should not be 
reported unless the investigator deems them to be possibly related to study interventi on.
Invest igators are not obligated to actively seek AEs or SAEs after c onclusion of the study  
participat ion(the participant summary CRF has been co mpleted) . However, if the invest igator 
learns o f any SAE, including a death, at any  time after a participant has been discharged from the 
study , and he/she considers the event to be reasonably related to the study  intervent ion or study  
participat ion, the invest igator must prompt ly notify  the sponsor.
8.3.2. Method of Detecting AE and SAEs 
The m ethod of recording, evaluat ing, and assessing causalit y of AE and SAE and the procedures 
for com pleting and transmitt ing SAE reports are provided in Section 10.3, Appendix 3. 
CONFIDENTIAL I3Y-MC-JPCY (b)
58Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and non -
leading verbal questioning of the participant is the preferred m ethod to inquire about AE 
occurrences. 
8.3.2.1. Serious Adverse Events
An SAE is any  AE from this study  that resul ts in 1 of the f ollowing outcom es:
death
initial or prolonged inpatient hospi talizat ion
a life- threatening experience (that is, immediate risk of dying)
persistent or significant disabili ty/incapacit y
congenital ano maly/birth defect
important medicalevents thatmay not beimmediately life-threatening orresult in death 
or requi re hospi talizati on may be considered serious when, based upon appropriate 
medical judgment, they  may jeopardi ze the participant and may require intervention to
prevent oneoftheother outcom eslisted inthedefinit ionabove. 
Planned hospi talizat ions or procedures for preexisting condit ions that were recorded in the 
participant ’s medical history  at the time of enrollment should not be considered SAEs.
Hospitalization or prolongat ion of hospitalizat ionwithout a preci pitating clinical AE (for 
example, for the administration of study  intervent ionor other protocol -requi red procedure) 
should not be consi dered SAEs .
Pregnancy (during maternal or paternal exposure to study  intervent ion) does not m eet the 
definition of an AE but should be reported. However, to fulfill regulatory requirements any 
pregnancy should be reported fo llowing the SAE process to collect data on the outcome for both 
mother and fetus. See Secti on 10.4, Appendix 4 ,for details. 
Suspected Unexpected Serious Adverse Reactions
Suspected unexpected serious adverse react ions (SUSARs) are serious events that are not listed 
in the IB and t hat the investigator ident ifies as related to study interventi onor study procedure. 
United States 21 CFR 312.32 and Regulat ion (EU) No 536/2014 and the associated detailed 
guidance or national regulatory  requi rements in parti cipating countri es requi re the reporting of 
SUSARs.  Lilly has procedures that will be fo llowed for the recording and expedited reporting of 
SUSARs that are consistent with global regulat ions and associated detailed guidance. 
8.3.3. Follow -up of AEs and SAEs
After the init ial AE/SAE report, the investigator is required to proactively fo llow each participant 
at subsequent visits/contacts. All SAEs will be fo llowed unt il reso lution to baseline , stabilizati on, 
the event is otherwise explained, or the participant dies or is lost to fo llow-up (as defined in 
Secti on7.3).Further informat ion on fo llow-up procedures is provi dedin Section 10.3, 
Appendix 3.
CONFIDENTIAL I3Y-MC-JPCY (b)
598.3.4. Regulatory Reporting Requirements for SAEs
Prom pt notificat ion by the invest igator to the sponsor of a SAE is essent ial so that l egal 
obligat ions and ethical responsibilit ies towards the safet y of parti cipants and the safet y of a study  
intervent ion under clinical investigat ion are m et.
The sponsor has a legal responsibilit y to notify both the l ocal regulatory  authori ty and other 
regul atory  agencies about the safet y of a study  intervent ion under clinical investigation. The 
sponsor will co mply wi th country -specific regulatory  requi rements relating to safet y reporti ng to 
the regulatory  authori ty, Inst itutional Review Boards (IRB)/Independent Ethics Committees 
(IEC), and invest igators.
An invest igator who receives an invest igator safety report describing a SAE or other specific 
safet y informat ion (e.g., summary or list ing of SAEs) from the sponsor will review and then file 
it along wi th the IBand will notify the IRB/IEC, if appropriate according to local requirements.
8.3.5. Pregnancy
Details o f all pregnancies in female partners of male participants will be c ollected after the start 
of study  intervent ionand until 3 weeks following cessat ion of study  intervent ion.
If a pregnancy  is reported, the investigator should inform the sponsor within 24 hours of learning 
of the pregnancy  and shoul d follow the procedures outlined in Section 10.3, Appendix 3.
Abnorm al pregnancy outcom es (e.g., spontaneous abortion, fetal death, stillbirth , congenital 
anomalies, ectopi c pregnancy ) are considered SAEs.
8.3.6. Adverse Events of Special Interest
More informat ion about the adverse events of special interest for abemaciclib can be found in th e 
IB. 
8.3.7. Complaint Handling
A product complaint is any written, electronic, or oral communicat ion that alleges deficiencies 
related to the identit y, qualit y,durabilit y, reliabilit y, safety, effect iveness or performance o f a 
trial intervent ion.
Lilly collects product complaints on invest igational products and drug delivery systems used in 
clinical studies in order to ensure the safet y of study  parti cipants, m onitor quali ty, and to 
facilitate process and product improvements.
Parti cipants will be instruct ed to contact the invest igator as soon as possible if he has a complaint 
or probl em with the investi gational product so that the situation can be assessed.
NOTE:  AEs/SAEs that are associated with a product complaint will also fo llow the processes 
outlin ed in Sections8.3.3 and10.3, Appendix 10.3, of the protocol.
8.4. Treatment of Overdose
In the event of an overdose, the invest igator should: 
Contact the Lilly CRP/CRS immediately . 
Closely  monitor the parti cipant f or any  AE/SAE and laboratory  abnorm alities. 
CONFIDENTIAL I3Y-MC-JPCY (b)
60Obtain a sample for PK analysis as soon as possible after the overdose has been 
ident ified, unless the Lilly  CRP/CRS specifies otherwise . 
Docum ent the quanti ty of the excess dose as well as the duration of the overdose. 
Decisio ns regarding dose interruptions or modifications will be made by the invest igator in 
consultation wit h the Lilly CRP/CRS based on the clinical evaluat ion of the parti cipant.
8.5. Pharmacokinetics
Pharmacokinet icsamples will b e collected to determine the concentrations of abemaciclib and its 
active metabo lites, LSN3106726 (M20)and LSN2839567 ( M2).  Blo od sam ples for PK analysis 
will be co llected by
1)venous puncture collect ion into a vacutainer , and 
2)capillary puncture collection into a v olumetri c absorpti ve microsampling device .
At the visit s and t imes specified in the SoA (Secti on 1.3.1 ),both a venous blood sample and a 
blood microsample should be collected at approximately the same time ( within [+/-] 10 minutes )
Pharmacokinet icsamples will be analyzed at a laboratory  approved by the sponsor and stored at 
a facilit y designated by the sponsor. Concentrations o f abemaciclib and i ts metaboli tes,M2 and 
M20 ,will be determined using validated liquid chromatography with tandem mass spectrom etry 
methods .
Pharmacokinet icsamples will be retained for a maximum o f 1 year following l ast subject visit 
for the study . 
A maximum of3samples m ay be collected at additional t ime po ints during the study  if 
warranted and agreed upon between both the investigator and sponsor.  Instructions for the 
collect ion and handling of blood samples will be provided by the sponsor .  The actual date and 
time (24-hour clock time) of each sampl ewill be recorded.
8.5.1. Patient Diary
A diary  will be provi ded to participants in order to help track date and time of each dose taken 
the day  before pl anned PK sample co llection.  Patient diary  evaluat ions will occur through Cy cle 
3 Day  1.  Refer to SoA (Secti on 1.3)foradditional informat ion.
8.6. Pharmacodynamics
See Secti on 8.8.Samples co llected will be ident ified by the partici pant number (coded) and 
retained at a facilit yselected by  Lilly  for a m aximum  of 15 y ears fo llowing the last participant
visit for the study.  
8.7. Genetics
8.7.1. Whole Blood Sample for Pharmacogenetic Research 
CCI
CONFIDENTIAL I3Y-MC-JPCY (b)
618.8. Biomarkers
8.8.1. Tissue Samples for Biomarker Research
Tissue samples for bio marker research will be collected for the purposes described in Sect ion
8.8.The fo llowing tissue samples for bi omarker research will be collected according to 
Secti on1.3.1 , where local regulations allow.
CCI
CCI
CONFIDENTIAL I3Y-MC-JPCY (b)
62Collect ion of the fo llowing tum or tissue sample(s) is required for all participants in order to 
participate in this study :
Mandatory  tumor biopsy  of at least 1metastatic site which will be collected fo llowing 
determinat ion of eligibilit y and before init iating study  intervent ion.
oBiopsy  of newly emerged radiographic metastases is preferable to the biopsy of 
previously exist inglesions whenever possible.
oSoft-tissue,as well as bony  metastati c lesions will be considered acceptable.  
Soft-tissue biopsy  is preferred to bone biopsy whenever possible.
At the time of tissue co llection, it is highly  recommended to confirm adequate tum or tissue (not a 
norm al adjacent ti ssue sample or a tumor margin sample) has been sampled. 
Adequate archival metastatic tissue can be used if available in lieu of a new biopsy  if the bi opsy 
was done within 12 weeks prior to enrollment AND no treatment was initiated from  biopsy  to 
study  entry .Sites shoul d confirm  availabilit y of archival tissue with pathology  laboratory  prior 
to study  entry .
An o ptional biopsy of metastatic l esion at the time of radiographic progression shoul d only be 
considered if the participant has completed at least 4 cycles of study  intervent ion.The biopsy o f 
a newly  emerged or a progressing metastasis is preferred over a pre -exist ing lesion that is not 
progressing ,whenever possible .
The pathology  report accom panying archival t issue may also be requested.  The pathology  report 
must be coded with the patient number.  Personal ident ifiers, including the patient’s name and 
initials, must be removed fro m the inst itutional pathol ogy report pri or to submissio n.Lilly has a 
right to retai n a porti on of  the submitted tissue.
Archival blocks will be sect ioned and returned to study  siteupon request . Slides and t umor 
tissue samples co llected as part of this study will not be returned.
Samples will  be retained at a facilit y selected by  Lilly  or its designee for a m aximum  of 15years 
after the l ast pati ent vi sit for the study , or f or a shorter period if local regulations and/or 
ERBs/IRBs impose shorter time limits.  This retentio n peri od enables the use of new 
techno logies, response to question s from regul atory  agencies, and invest igation of variable 
response that may not be observed unt il later.
Techno logies are expected to improve during the 15 -year storage period, and therefore, cannot 
be specifically named.  Exist ing approaches, including mu tation profiling, copy  number 
variabilit y analysis, gene expressio n assays, mult iplex assays, and/or immunohistochemistry  may 
be perform ed on these ti ssue samples to assess potent ial associ ations between these bio markers 
and clinical outcomes.
8.8.2. Other Sample s for Biomarker Research
CCI
CONFIDENTIAL I3Y-MC-JPCY (b)
638.9. Immunogenicity Assessments
Not applicable.
8.10. Health Economic s
8.10.1. Patient reported outcomes
The m ain object ive of the patient reported outcome (PRO) measurement is to assess pat ient 
reported tolerabilit y (i.e.,assessment of symptomatic AEs).  In addi tion, the m easurement of 
PROs will focus on the overall side effect imp act, di sease related symptom s, specifically pain, 
and well as physical funct ioning and global healt h related quali ty of life. 
Patient reported symptomatic AEs will be measured using The Nat ional Cancer Inst itute’s PRO 
versio n of the commo n termino logy cri teria for adverse events (PRO -CTCAE) 
(http://healthcaredelivery.cancer.gov/pro -ctcae/).  The choiceof PRO- CTCAE symptom s items 
selected fro m the PRO- CTCAE item library  is aligned wit h the recommendat ions published in 
Trask et al. 2018.  
 
 
 
 
 
Addit ionally , the GP5 item of the Funct ional Assessment of 
Cancer Therapy -General  (FACT -G) instrument , which asks participants to report the extent to 
which “(they  are) bothered by  side-effects of treatment”, will be administered to assess overall 
side-effect burden.
CCI
CCI
CONFIDENTIAL I3Y-MC-JPCY (b)
64The impact of abemaciclib on pain will also be explored using the 7-day Worst Pain N umeric 
Rating Scale (NRS) data and analgesic use.   The 7-day Worst Pain NRS is a single -item 
questionnaire which measures worst pain over the last 7 day son a 0 to10point numeric rating 
scale , where 0 i s ‘no pain’ and 10 is ‘pain as bad as y ou can imagine’. Data on over -the-counter 
and prescription analgesic medicat ions including dose, unit, frequency, and route of 
administration will be collected by  site personnel  and recorded in the CRF. Analgesic use will 
be classified into categories, for example, according to the World Health Organizati on analgesic 
ladder or the Analgesic Quant ificat ion Algorithm scale.
Physical funct ioning and overall healt h-related qualit y of life will be measured using the 
Physical Funct ioning and Global Heal th Status/ Qualit y of Life ( QoL)scales of the European 
Organizat ion for the Research and Treatment of Cancer Qualit y of Life Quest ionnaire (EORTC
QLC -C30).  Both the GP5 item and EORTC QLQ-C30 i tems are m easured on a 5 -point Likert 
scale , from ‘not at all ’to ‘very much’.
The PRO -CTCAE ,FACT -GP5, 7- day Worst Pain NRS, and EORTC QLQ -C30 Physical 
Funct ioning and Glo bal Healt hStatus /QoLscales will be a dministered at baseline (screening) , 
Day 1 of every cycle, treatm ent di scont inuat ion, and short -term follow-up. Questionnaires 
shoul d be com pleted by all participants where there is a validated language/cultural translation 
available in which the pat ient is fluent . The questionnaires should be completed before any 
extensive contact and consultation wit h the clinician/study  invest igator ,as such encoun tersmay 
thereafter bias patient responses . Questionnaires shoul dbe administered in the fo llowing order: 
7-day Worst Pain NRS , then PRO- CTCAE, then FACT -GP5, and finally  the QLQ -C30 Physical 
Funct ioning and Glo bal Healt h Status/QoL scales .
8.10.2. Health Care Resource Utilization
Health care resou rces utilization data, associated wit h medical encounters, will be collected in 
the eCRF by the invest igator or authori zed study  perso nnelfor all participant s throughout the 
study .  Protocol -mandated procedures, test s, and encounters are excluded.
The data collected may be used to conduct economic analyses and will include hospi talizati ons 
and emergency room visits (reason and duration).
CONFIDENTIAL I3Y-MC-JPCY (b)
659. Statistical Considerations
9.1. Statistical Hypotheses
The stati stical hypothesis o f this study is that there will be a clinically relevant rate of response to 
abemaciclib mo notherapy  administered to patients with mCRPC that ha vebeen previously 
treated with at least 1 novel androgen -axis therapy (androgen -synthesis or receptor inhibitor, 
such as abiraterone acetate, apalutamide, darolutamide or enzalutamide) and 2 taxane regimens 
(docetaxel, cabazitaxel) .
9.2. Sample Size Determination
Approximately 40 participants will be assigned to study  interventi on.  All  treated pati ents will  be 
included in the assessment of objective response, with patients lacking a complete disease 
assessment per RECIST 1.1 criteria at eit her baseline or at any t imepostbaseline being classified 
as non -responders.
An observed res ponse rate of at least 12.5% in 40 partic ipants will be considered as evidence o f 
clinically relevant activit y, which yields an adequate Ty pe I error rate and power. As an 
illustrati on of  Type I error control, assuming a true response rate of 5%, the proba bility of 
observing an ORR of at least 12.5% in a cohort of 40 participant s is 4.8%. As an illustration of 
power, assuming a true response rate of 15%, the probabilit y of observing an ORR of at least 
12.5% i s 73.7%.   
9.3. Populations for Analyses
The following popul ations are defined:
Population Description
Entered All participants who sign the ICF
Treat ed/Safet y All participants who have init iated study  intervent ion, regardless 
of how m any doses of  study  interventi onthey receive or how 
many on -study  research procedures are performed.
Biomarker Evaluable All participants within the subset of parti cipants from  theTreated 
popul ation from whom a valid pre-treatm ent tum or assay result has 
been obtained.
Pharmacokinet ic Analysis All treated participants who received at least 1 dose of abemaciclib
and have at least 1 evaluable PK sample.
Abbreviations: ICF = informed consent form; PK = pharmacokinetics .
CONFIDENTIAL I3Y-MC-JPCY (b)
669.4. Statistical Analyses
9.4.1. General considerations
Statistical analysis o f this study  will be the responsibil ity of the sponsor or i ts desi gnee.
This is an uncontrolled trial o f abemaciclib, so in general, inferential statist ical tests of treatment 
will not be perfo rmed.  All tests of effects between subgroups of participant s will be conducted 
at a 2 -sided alpha level o f 0.05, unl ess otherwise stated, and all CIs will be given at a 2- sided 
95% l evel.
For all response -based evaluat ions of endpo int change fro m baseline, e.g. ,best overall response 
(BOR )by RECIST 1.1, PCWG 3, or PSA value, the baseline value will be the last observati on 
taken before treatment init iation that falls wit hin the specified timeframe.  Participant s without 
an observat ion in this timeframe will be considered non- evaluable f or the associ ated response.
Any change to the data analysis methods d escribed in the protocol will require an amendment 
only if it changes a princi pal feature of the protocol.  Any other change to the data analysis 
methods described in the protocol, and the just ification for making the change, will be described 
in the SAP a nd the clinical study  report.  Addi tional expl oratory  analyses of the data will be 
conducted as deemed appropriate.
The SAP will be finalized prior to First Pati ent Fi rst Vi sitand i t will include a m ore technical 
and detailed descript ion of the statistica l analyses described in this sect ion. This sect ion is a 
summary of the planned statist ical analyses of the most important endpoints including primary 
and key  secondary endpoints.
9.4.2. Primary analysis
The primary  analysis of the primary  endpoint of ORR will be performed approximately  6 months 
after the l ast pati ent enters treatment and/or invest igator -assessed best response assessments have 
been co mpleted for all participant s.  All secondary endpo ints will be evaluated at this time. 
Addit ional updated analyses of efficacy and safet y may be conducted at later times if deemed 
appropriate by  the sponsor.   
At each analysis, the ORR will be evaluated against a null hypothesis of 5%. For the interim 
analysis of efficacy , all participant s who have init iated treatm ent more than approximately  
16weeks prior to the data cut -offwill be considered part of the at -risk popul ation.  For the 
primary  analysis, responders will consist of those participant s with a BOR of confirmed PR or 
confirmed CR, per RECIST 1.1 criteria , and do not have concurrent bone progression per 
PCW G3 at the time of the analysis. If 5 or m ore responders are observed from 40 treated 
participants , the study  will be considered positive.This is equivalent to evaluat ing the binomial 
exact test with a nul l hypothesis that the ORR is 5% against an alternat ive of an ORR greater 
than 5% at a one -sided α =0.05.
Lilly or i ts desi gnee will  collect and store tum or assessment images, and an independent review 
of imaging scans may be performed by Lilly or its des ignee. Summaries of endpo ints using 
independent ly reviewed BOR may be presented as sensit ivity analyses, as described in the SAP.
CONFIDENTIAL I3Y-MC-JPCY (b)
679.4.3. Secondary endpoint(s)
Summaries of event rates, including radio logic ORR, and PSA-based response, will be defined as 
the proporti on of  all treated participant s who achieve the specified response category .  
Parti cipants with a non -evaluable or unknown response per specified criteria will be considered 
non-responders for the purpose o f calculat ing the response rate.
Detailed censoring rules for time to event ( TTE)endpo ints are described in the SAP.   For all 
TTE endpoints, median event times and rates at various time po ints,with 95% CI, will be 
estimated using the Kaplan- Meier method (Kaplan and Meier 1958).  Sensit ivity analyses for 
TTE will be described in the SAP.
9.4.4. E xploratory endpoint(s)
9.4.5. Other Safety Anal yses
All safet y analyses will be made on the Safet y Popul ation, defined as all participant s who receive 
at least 1 dose of study  drug will be evaluated for safet y and toxi city.
The Medical Dictionary  for Regul atory  Activit ies (MedDRA®) Versi on[21.0 (or higher)] will be 
used when reporting AEs by MedDRA terms. The MedDRA Lower Level Term (LLT) will be 
used in the treatment -emergent com putati on.Treatment -emergent adverse events (TEAEs) will 
be summarized by System Organ Class (SOC) and by decreasing fre quency of Preferred Term 
(PT) wi thin SOC.
Safety analyses will include summaries of the fo llowing:
TEAEs , including severit y and possible rel ationship to study  drug
Treatment -emergent SAEs , incl uding possible relati onship to study  drug
AEs leading to dose adjust ments
discontinuat ions from  study  interventi ondue to adverse events or death
treatm ent-emergent abnormal changes in laboratory values
treatm ent-emergent abnormal changes in vital signs
The number of participant s with dose reducti ons, dose delays, o r dose omissions will be 
summarized, as will the reasons for dose adjust ments.
Reasons for death will be summarized separately for on -therapy  and wi thin 30 days of treatment 
discontinuat ion.
9.4.6. Other Analyses 
9.4.6.1. Participant Disposition
A detailed description o fpatient di sposi tion will be provi ded, including a summary  of the 
number and percentage of participant s enrolled in the study , and treated, as well as number and 
percentage of participant s com pleting the study, as defined in the SAP, or discont inuing (over all 
and by  reason for di scont inuat ion).  A summary  of all  important protocol  deviat ions will be 
provi ded.
CCI
CONFIDENTIAL I3Y-MC-JPCY (b)
689.4.6.2. Participant Characteristics
A summary of participant demographics, baseline participant and disease characteri stics, 
histori cal diagnoses, preexist ingcondi tions, and prior anti-cancer therapies will be reported using 
descript ive statistics .
Other participant characterist ics will be summarized as deemed appropriate.
9.4.6.3. Treatment Compliance
Treatment compliance will be summarized for all treated participant s.
Com pliance inform ation for study  drug will be collected by counting any remaining tablets at 
each cy cle.  The est imate of percent compliance will be given by: 
Percent Com pliance = Actual  cumulat ive dose taken × 100
        Expected cumulative dose to be taken
The actual  cum ulative dose taken will be determined based on counting the number of tablets 
returned at each visit and subtracting that number from the number of tablets dispensed. The 
expected cumulat ive dose to be taken will be determi ned based on the assigned dose and taking 
into account any  dose reducti ons or omissions .
9.4.6.4. Extent of Exposure
The number of cycles received ,dose omissio ns, dose reductions, dose delays, and dose intensit y 
will be summarized for all treated participant s.
9.4.6.5. Post-Abemaciclib Therapy
The numbers and percentages of participant s receiving post -study -treatm ent discont inuat ion 
anticancer therapies will be provided by t ype of therapy  (surgery , radi otherapy , or systemic 
therapy ), and by drug cl ass and/or nam e, overall a nd by line of therapy .
9.4.6.6. Pharmacokinetic /Pharmacodynamic Analyses
Pharmacokinet icanalyses will be conducted on all participant s who have received at least 1 dose 
of abemaciclib and have at least 1 evaluable PK sample.
Abemaciclib PK analyses may include, bu t are not limited to:
(1)Summary  analyses of individual and/or mean concentrations of abemaciclib, M2 and 
M20, grouped by  analy te, dose l evel, time point, etc .
(2)Popul ation PK modeling analysis to evaluate populat ion PK parameters and inter -
individual PK variab ility.
Relationships between exposure and measures o f efficacy  and safet y may be explored.
9.4.6.7. Patient Reported Outcomes
Patient Reported Outcomes will be analyzed using d escriptive statistics will be calculated for 
patient-reported data for each instrument.  Further details will be described in the PRO SAP.
CONFIDENTIAL I3Y-MC-JPCY (b)
699.4.6.8. Biomarker Analysis
The percentage of cells expressing Ki- 67 by  immunohistochemistry  (IHC)for each participant in 
thebiomarker evaluable population will be summarized and listed. Addit ionally , Ki-67 
expressio n values will be classified into a series of binary variables (e .g.,<10%, <25%, etc .; see 
SAP for details), and the proportion of participants in each group will be reported with 
corresponding exact 95% CIs. Given a sample size of 40 patients, corresponding exact 95% CIs
for a vari ety of observed prevalence rates are illustrated below.
Observed Prevalence Rate 95% Confidence Interval
0.05 (0.006, 0.169)
0.25 (0.127, 0.412)
0.5 (0.338, 0.662)
0.75 (0.588, 0.873)
0.95 (0.831, 0.994)
9.4.6.9. Subgroup Analyses 
A prespecified list of subgroups will be ident ified in the SAP. The treatment effect within each 
subgroup will be summarized. Other subgroup analyses not specified in the SAP may be 
perform ed as deemed appropriate. These subgroups will be based on important characterist ics, 
for example, prognostic significance .
9.5. Interim Analyses 
A futility analysis will  be conducted approximatel y 2 months after the 15thparticipant has 
entered treatment. Trial enrollment will cont inue while await ing the results of the fut ility 
analysis. The study  team  will consider the totalit y of safet y, efficacy, and PK data. As guidance, 
futilit y shoul d be declared and trial enrollment stopped if 0 patients have achieved an 
unconfirmed PRor CRper RECIST 1.1 AND fewer than 5 parti cipants have achieved a BOR of
SDper RECIST 1.1 at the time o f the futility analysis.
One additionalinterim analys isof efficac ywill be conducted approximately 2 mo nths after all 
participant s have entered treatment .  Endpoints using RECIST 1.1 will be analyzed considering 
both confirmed and unconfirmed responses. The interim analys iswill be conducted to evaluate 
the initial evidence of ant itumor activit y. The sponsor has no intent to stop the study  based on 
the interim analysis o f antitumor activit y and all participant s will cont inue follow-up for all  study  
objectives unt il study  close.
Addit ional interim analysis may  be con ducted as deemed appropriate by the sponsor.
The SAP will describe the planned int erim analyses in greater detail .
9.6. Data Monitoring Committee (DMC)
Not applicable.
CONFIDENTIAL I3Y-MC-JPCY (b)
7010. Supporting Documentation and Operational Considerations
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance wit h the protocol and with the fo llowing:
oConsensus ethical principles derived from international guidelines including the 
Declaration of Helsi nki and CIOMS Internat ional Ethical Guidelines
oApplicable Internat ional Council for Harmonisation ( ICH) Good Clinical Practice 
Guidelines
oApplicable laws and regulations
The protocol, protocol amendments, ICF, IB, and other relevant documents (e .g., 
advert isements) must be submitted to an IRB/IEC by the investigator and reviewed and 
approved by  the IRB/IEC before the study  is init iated.
Any amendments to the protocol will require IRB/IEC approval before implementation 
of changes made to the study design, ex cept for changes necessary  to eliminate an 
immediate hazard to study  parti cipants.
The invest igator will be responsible for the fo llowing:
oProvi ding wri tten summaries of the status of the study  to the IRB/IEC annually  or 
more frequent ly in accordance wit h the requirements, policies, and procedures 
established by  the IRB/IEC
oNotifying the IRB/IEC of SAEs or other significant safet y findings as required by 
IRB/IEC procedures
oProvi ding oversight of the study  conduct forthe participants under their responsibilit y
and adherence to requirements of 21 CFR, ICH guidelines, the IRB/IEC, European 
regul ation 536/2014 for clinical studies (if applicable), and all other applicable local 
regul ations.
oInvest igator sites are compensated for participat ion in the study  as de tailed in the 
clinical trial agreement.
10.1.2. Financial Disclosure
Invest igators and sub -invest igators will provide the sponsor with sufficient, accurate financial 
inform ation as requested to allow the sponsor to submit complete and accurate financial 
certificat ion or di sclosure statem ents to the appropri ate regul atory  authori ties. Invest igators are 
responsible for providing informat ion on financial interests during the course of the study  and for 
1 year after complet ion of the study .
CONFIDENTIAL I3Y-MC-JPCY (b)
7110.1.3. Informed Consent Process
The invest igator or his/her representative will explain the nature of the study , including 
the risks and benefits, to the parti cipant or hi s/her legally authorized representative and 
answer all quest ions regarding the study .
Parti cipants m ust be inform ed that thei r parti cipat ion is vo luntary. Participants or thei r 
legally authorized representative will be required to sign a statement of informed 
consent that meets the requirements of 21 CFR 50, local regulat ions, ICH guidelines, 
Health Insurance Portabilit y and Accountabilit y Act requi rements, where applicable, 
and the I RB/IEC or study  center.
The m edical  record m ust include a statem ent that wri tten inform ed consent was 
obtained before the participant was enter ed in the study  and the date the written consent 
was obtained. The authorized person obtaining the informed consent must also sign the 
ICF.
Parti cipants m ust be re -consented to the most current versio n of the ICF(s) during th eir 
participat ion in the study.
A copy  of the ICF(s) m ust be provi ded to the participant or the participant’s legally  
authori zed representati veand i s kept on file .
Parti cipantswho are rescreened are required to sign a new ICF.
10.1.4. Data Protection
Parti cipants will be assigned a unique identifier by the sponsor. Any participant 
records ,datasets or tissue samples that are transferred to the sponsor will contain the 
ident ifier only; part icipant names or any  information which would make the participa nt 
ident ifiable will not be transferred.
The parti cipant must be inform ed that hi s/her personal  study -related data will  be used 
by the sponsor in accordance wit h local data protecti on law. The level o f disclosure 
must al so be explained to the participant who will be required to give consent for their 
data to be used as described in the informed consent .
The parti cipant must be inform ed that hi s/her m edical  records m ay be examined by 
Clinical Qualit y Assurance auditors or other authorized personnel appo inted by the 
sponsor, by  appropriate IRB/IEC members, and by inspectors from regulatory  
authori ties.
The Sponsor has processes in place to ensure data protection, informat ion securit y and 
data integrit y.  These processes include appropriate contingency plan(s) for appropri ate 
and timely response in the event of a data securit y breach .
10.1.5. Committees Structure
Not applicable.
CONFIDENTIAL I3Y-MC-JPCY (b)
7210.1.6. Data Quality Assurance
All participant data relat ing to the study  will be recorded on printed or electronic CRF 
unless transmitted to the spon sor or desi gnee electronically (e .g., laboratory  data). The 
investigator is responsible for verifying that data entries are accurate and correct by  
physically or electronically signing the CRF.
The invest igator must maintain accurate documentation (source data) that supports the 
inform ation entered in the CRF.
The invest igator must permit study -related m onitoring, audi ts, IRB/IEC review, and 
regul atory  agency inspecti ons and provi de di rect a ccess to source data documents.
Moni toring details describing stra tegy (e.g., risk -based init iatives in operations and 
qualit y such as Risk Management and Mit igation Strategies and Analyt ical Risk-Based 
Moni toring), m ethods, responsibilit ies and requirements, including handling of 
nonco mpliance issues and monitoring tech niques are provi ded in the Monitoring Plan.
The sponsor or designee is responsible for the data management of this study  includin g 
qualit y checking of the data.
The sponsor assumes accountabilit y for acti ons delegated to other individuals (e.g ., 
Contract R esearch Organizations).
Study  monitors will perform  ongoing source data verification to confirm that data 
entered into the CRF by authorized site personnel are accurate, complete, and verifiable 
from source docum ents; that the safet y and ri ghts of  parti cipants are being protected; 
and that the study  is being conducted in accordance with the currently approved 
protocol  and any  other study  agreements, ICH GCP, and all applicable regu latory  
requi rements.
Records and documents, including signed ICFs, pertaining to the conduct of this study  
must be retained by the invest igator for the time period outlined in the Clinical Trial 
Agreement unless local regulations or inst itutional policies require a longer retention 
period. No records may be destroy ed during the retention period without the written 
approval  of the sponsor. No records may be transferred to another location or party 
without wri tten notificat ion to the sponsor .
In addit ion, the sponsor or its representatives wi ll periodically  check a sample of the 
participant data recorded against source documents at the study site.  The study may be 
audited by  the sponsor or its representatives, and/or regulatory  agencies at any  time.  
Invest igators will be given notice before an audit occurs.
Data Capture System
The invest igator is responsible for ensuring the accuracy, completeness, legibilit y, and timeliness 
of the data reported to the sponsor. 
An electronic data capture sy stem  (EDC) will be used in this study  for the collec tion of  CRF 
data.  The investigator maintains a separate source for the data entered by  the invest igator or 
designee into the sponsor -provided EDC system.  The invest igator is responsible for the 
CONFIDENTIAL I3Y-MC-JPCY (b)
73ident ificat ion of any data to be considered source and for t he confirmat ion that data reported are 
accurate and complete by  signing the CRF .
Addit ionally , electroni c Clinical Outcom e Assessment (eCOA) data (participant -focused 
outcom e instrument ) will be directlyrecorded by the participant into an instrument (for example , 
handheld smart phone or tablet, or by means of an interact ive vo ice/web system ).  The eCOA 
data will serve as the source documentation and the invest igator does not maintain a separate , 
written or electronic record of these data.
Data collec ted via the sponsor -provided data capture system will be stored at third party. The 
investigator will have cont inuous access to the data during the study  and unt il deco mmissio ning 
of the data capture sy stem .  Pri or to decommissio ning, the invest igator wil l receive an archival 
copy  of pertinent data for retention.
Data m anaged by  a central  vendor, such as laboratory  test data, will be stored electronically  in 
the central  vendor’s database system and the results will be provided to the investigator for 
revie w and retenti on.  Data will subsequent ly be transferred fro m the central  vendor to the Lilly  
data warehouse.   Data from co mplaint forms submitted to sponsor will be encoded and stored in 
the global product complaint management sy stem .
10.1.7. Source Documents
Source documents provide evidence for the existence of the participant and substantiate 
the integrit y of the data collected. Source documents are filed at the invest igator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source 
docum ents m ust be consistent with the source documents or the discrepancies must be 
explained.  The investigator may  need to request previous medical records or transfer 
records, depending on the study. Also, current medical records must be available.
10.1.8. Study and Site Start and Closure
The study  start date is the date on which the clinical study  will be open for recruit ment of 
participants.
The first act of recrui tment i s the first site open and will be the study  start date.
The sponsor designee reserves the right to close the study  site or terminate the study  at any  time 
for any  reason at the sol e discret ion of the sponsor. Study  sites will be cl osed upon study  
completion. A study  site is considered closed when all required documents and study  supplies 
have been co llected and a study -site closure visi t has been perform ed.
The invest igator may init iate study -site closure at any  time, provi ded there i s reasonable cause 
and sufficient notice is given in advance of the intended terminat ion.
Reasons for the early closure of a study  site by the sponsor or investigator may  include but are 
not limited to:
Failure of the invest igator to comply wit h the protocol, the requirements of the IRB/IEC 
or local health authori ties, the sponsor's procedures, or GCP guidelines
Inadequate recruit ment of parti cipants by  the investi gator
Discontinuati on of  further study  intervent ion developm ent.
CONFIDENTIAL I3Y-MC-JPCY (b)
74If the study  is prem aturely  terminated or suspended, the sponsor shall prompt ly inform the 
investi gators, the IECs/IRBs, the regulatory  authorit ies, and any contract research organizat ion(s) 
used in the study  of the reason for terminat ion or suspensio n, as specified by the applicable 
regul atory  requi rements. The invest igator shall prom ptly inform  the participant and should 
assure appropriate participant therapy  and/or fo llow-up .
10.1.9. Investigator Information
Physicians with a specialt y in onco logywill participate as invest igators in this clinical trial.
CONFIDENTIAL I3Y-MC-JPCY (b)
7510.2. Appendix 2: Clinical Laboratory Tests
The tests detailed belowwill be performed as indicated in the table .
Local  laboratory  resul ts are only  required in the event that the central laboratory  resul ts are not 
available in t ime for inclusio n/exclusio n determinati on,study  intervent ion admi nistrati on and/or 
response evaluat ion.If a local sample is required, it is important that the sample for central 
analysis is also obtained. If there is an abnormal laboratory value or abnormal value for any 
other diagnost ic or screening test (for exampl e, blood pressure increased, neutrophils decreased, 
etc.) and it is known to be related to a diagnosis (for example, hypertensio n, neutropenia, etc.) 
this shoul d be reported in the CRF.  Do not enter the test abnormalit y, enter the diagnosis or 
categori calterm.
Addit ional tests may be performed at any  time during the study  as determined necessary  by the 
investigator or required by  local regulati ons and clinically significant findings should be reported 
in the CRF as an AE.
Enrollment and treatment decisions may  be based on l ocal laboratory  resul ts. A sample must 
still be sent to the central laboratory . Differences between these samples will not be considered a 
protocol  deviat ion.
CONFIDENTIAL I3Y-MC-JPCY (b)
76Hematology –a, c
Leukocy tes (WBC) Basophils
NeutrophilsbErythrocytes (RBC)
Lymphocy tes Hem oglobin (HGB)
Monocy tes Hem atocri t (HCT)
Eosinophils Platelets (PLT)
Mean corpuscular vo lume (MCV) Mean corpuscular hemoglo bin concentrati on 
(MCHC)
Clinical chemistry –a, c
Serum  concentrati ons of : 
Alanine aminotransferase (ALT) Cystatin C
Albumin Glucose (random )
Alkaline phosphatase High-densit y lipoprotein (HDL)
Aspartate aminotransferase (AST) Lactic acid dehydrogenase (LDH)
Bilirubin, direct Low-densit y lipoprotein (LDL)
Bilirubin, total Magnesium
Bicarbonate/CO 2 Phosphate
Blood urea ni trogen (BUN) or bl ood urea Potassi um
Calcium Protein
Chloride Sodium
Cholesterol Triglycerides
Creatinine Urate
Creatinine kinase (CK)
Other Tests -a, c
PSA Testosterone
Abbreviations:  CO 2 = carbon dioxide; CRF = case report form; PSA = prostate specific antigen; RBC = red blood 
cells; WBC = w hite blood cells.
aCentral laboratory.  
bNeutrophils reported by automated differential hematology instruments include both segmented and band forms . 
When a manual differential is needed to report the neutrophils, the segmented and band forms should be added 
together and recorded on the CRF, unless the CRF specifically provides an entry field for bands.
cEnrollment and treatment decisions may be bas ed on local laboratory results . A sample must still be sent to the 
central laboratory. Differences between these samples will not be considered a protocol deviation . 
CONFIDENTIAL I3Y-MC-JPCY (b)
7710.3. Appendix 3: Adverse Events:  Definitions, and Procedures for 
Recording, Evaluating, Follow -up and Reporting
10.3.1. Definition of AE
AE Definition
An AE is any  untoward m edical occurrence in a participant or clinical study  parti cipant, 
temporally  associ ated wi th the use of study  intervent ion, whether or not considered 
related to the study  intervent ion.
NOTE:  An AE can therefore be any  unfavorable and unintended sign (including an 
abnorm al laboratory  finding), symptom, or disease (new or exacerbated) temporally 
associ ated wi th the use of study  intervent ion.
Events Meeting the AE Definition
Any abnormal laboratory  test resul ts (hematol ogy, clinical chemistry , or uri nalysis) or 
other safet y assessments (e.g., ECG, radio logical scans, vital signs measurements), 
including those that worsen fro m baseline, considered clinically significant in the medical 
and scient ific judgment of the invest igator (i.e., not related to progression of underlying 
disease).
Exacerbat ion of a chronic or intermittent pre -exist ing condit ion including either an 
increase in frequenc y and/or intensit y of the condi tion.
New condit ions detected or diagnosed after study  intervent ion administration even 
though it m ay have been present before the start of the study .
Signs, symptoms, or the clinical sequelae of a suspected drug -drug interac tion.
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study  
intervent ion or a concomitant medicat ion. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -harm ing 
intent. Such overdoses should be reported regardless of sequelae.
“Lack of efficacy” or “failure of expected pharmacological act ion” per se will not be 
reported as an AE or SAE. Such instances will be captured in the efficacy assessments. 
However, t he signs, symptoms, and/or clinical sequelae result ing fro m lack of efficacy 
will be reported as AE or SAE if they fulfill the definit ion of an AE or SAE.
Events NOT Meeting the AE Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underlying disease, unless judged by the 
investigator to be more severe than expected for the participant’s condit ion.
The disease/disorder being studied or expected progressio n, signs, or sym ptom s of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condi tion.
CONFIDENTIAL I3Y-MC-JPCY (b)
78Medical or surgical procedure (e.g., endoscopy , appendectomy): the condit ion that l eads 
to the procedure is the AE.
Situations in which an untow ard m edical occurrence did not occur (social and/or 
convenience admissio n to a hospital).
Anticipated day -to-day fluctuations of pre -exist ing disease(s) or condit ion(s) present or 
detected at the start of the study  that do not worsen.
10.3.2. Definition of SAE
Ifan event is not an AE per definit ion above, then it cannot be an SAE even if serious condit ions 
are met (e .g., hospitalizat ion for signs/symptoms of the disease under study , death due to 
progression of disease).
AnSAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
The term  'life-threatening' in the definit ion of 'serious' refers to an event in which the participant 
was at risk of death at the time of the even t. It does not refer to an event, which hypothetically 
might have caused death, if it were more severe.
c.Requires inpatient hospitalization or prolongation of existing hospitalization
In general, hospitalizat ion signifies that the participant has been admi tted to hospi talfor 
observat ion and/or treatment that would not have been appropriate in the physician’s 
office or outpatient setting. Com plicat ions that occur during hospitalizat ion are AEs. If a 
complicat ion prol ongs hospi talizati on or f ulfills an y other seri ous cri teria, the event i s 
serious. When in doubt as to whether “hospitalizatio n” occurred or was necessary , the 
AE should be considered serious.
Hospitalization for elect ive treatment of a pre -existing condit ion that di d not worsen fro m 
basel ine is not considered an AE.
d.Results in persistent disability/incapacity
The term disabili ty means a substant ial disrupt ion of a person’s abilit y to conduct norm al 
life funct ions.
This definit ion is not intended to include experiences of relat ively minor medical 
significance such as unco mplicated headache, nausea, vomit ing, di arrhea, influenza, and 
accidental  traum a (e.g., sprained ankle) which may interfere with or prevent every day life 
funct ions but do not constitute a substant ial disruptio n.
e.Is a conge nital anomaly/birth defect
f.Other situations:
Medical or scient ific judgment should be exercised in deciding whether SAE reporting is 
CONFIDENTIAL I3Y-MC-JPCY (b)
79appropriate in other situations such as important medical events that may  not be 
immediately  life-threatening or result in death or hospitalization but may jeopardize the 
participant or m ay requi re medical or surgi cal intervent ion to prevent one of the other 
outcom es listed in the above definit ion. These events should usually be considered 
serious.
Examples of such events include invasive or malignant cancers, intensive treatment in an 
emergency room  or at hom e for allergic bronchospasm, blood dy scrasias or convulsio ns 
that do not result in hospitalizat ion, or development of drug dependency or drug abuse .
10.3.3. Recording and Follow -Up of AE and/or SAE
AE and SAE Recording
When an AE/SAE occurs, it is the responsibilit y of the investigator to review all 
docum entati on (e.g., hospi tal progress notes, l aboratory  reports, and di agnosti cs reports) 
related to the event.
The invest igator will then record all relevant AE/SAE informat ion in the CRF.
It is notacceptable for the invest igator to send photocopies of the participant’s medical 
records to the sponsor or designee in lieu of completion of the AE/SAE CRF page.
There m ay be insta nces when copies of medical records for certain cases are requested by  
the sponsor or designee . In this case, all participant ident ifiers, with the exception of the 
participant number, will be redacted on the copies of the medical records before 
submissio n to the sponsor or designee .
The invest igator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical informat ion. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE .
Assessment of Intensity
The invest igator will use CTCAE v5.0 (NCI 2017 ) to assign AE severit y grades.
Assessment of Causality
The invest igator is obligated to assess the relationship between study  intervent ion and 
each occurrence of each AE/SAE.
A “reasonable possibilit y” of a relationship conveys that there are facts, evidence, and/or 
argum ents to suggest a causal relationship, rather than a relationship cannot be rul ed out.
The invest igator will use clinical judgment to determine the relat ionship.
Alternat ive causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event t o study  intervent ion 
administration will be considered and invest igated.
The invest igator will also consult the IB and/or Product Information, for marketed 
products, in his/her assessment.
For each AE/SAE, the invest igator must document in the medical note s that he/she has 
CONFIDENTIAL I3Y-MC-JPCY (b)
80reviewed the AE/SAE and has provided an assessment of causalit y.
There m ay be si tuations in which an SAE has occurred and the invest igator has minimal 
inform ation to include in the init ial report to Sponsor or designee. However, it is ve ry 
important that the invest igator always make an assessment of causalit y for every  event 
before the init ial transmissio n of the SAE data to Sponsor or designee.
The invest igator may change his/her opinio n of causalit y in light of fo llow-up 
inform ation and send a SAE follow -up report wi th the updated causalit y assessment.
The causalit y assessment is one of the cri teria used when determining regulatory  
reporting requirements.
Follow -up of AEs and SAEs
The invest igator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluat ions as medically indicated or as requested by Sponsor or 
designee to elucidate the nature and/or causalit y of the AE or SAE as fully as possible . 
This m ay include addit ional laboratory  tests or investigations, histopathological 
examinat ions, or consultation with other health care professio nals.
New or updated informat ion will be recorded in the originally co mpleted CRF.
The invest igator will subm it any updated SAE data to Sponsor or designee within 
24hours of receipt of the information.
10.3.4. Reporting of SAEs
SAE Reporting via an Electronic Data Collection Tool
The primary  mechanism  for reporting an SAE will be the electronic data collect ion tool .
If the electronic system is unavailable, then the site will use the paper SAE data 
collect ion tool  (see next secti on) in order to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem  as soon as i t becom es 
available.
After the study  is com pleted at a given site, the electronic data collect ion tool  will be 
taken off -line to prevent the entry  of new data or changes to exist ing data.
If a site receives a report of a new SAE fro m a study  parti cipant or receives updated da ta 
on a previously reported SAE after the electronic data collect ion tool  has been taken off -
line, then the site can report this informat ion on a paper SAE form (see next section) or to 
the medical mo nitorby telephone.
Contacts for SAE reporting can be found in the SAE form .
SAE Reporting via Paper CRF
Facsimile transmissio n of the SAE paper CRF is the preferred method to transmit this 
inform ation to the medical mo nitor.
In rare circumstances and in the absence of facsimile equipment, notificat ion by 
CONFIDENTIAL I3Y-MC-JPCY (b)
81telephone is acceptable wit h a copy  of the SAE data collect ion tool  sent by  overnight 
mail or courier service.
Initial notificati on via telephone does not replace the need for the invest igator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
Contacts for SAE reporting can be found in the SAE form .
CONFIDENTIAL I3Y-MC-JPCY (b)
8210.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information
Contraception Guidance:
CONTRACEPTIVES aALLOWED DURING THE STUDY INCLUDE (for study participants or their 
female partners if sexually active and if female partners are of childbearing age ):
Highly Effective Methods bThat Have Low User Dependency 
 Implantable progestogen -only  hormone contraception associated with inhibition of ovulation c
 Intrauterine device
 Intrauterine hormone -releasing system c
 Bilateral tubal occlusion
 Vasectomized partner
Vasectomized partner is a highly effective contraceptive method provided that the partner is the sole sexual 
partner of the woman of childbearing potential and the absence of sperm has been confirmed.  If not, an 
additional highly effective method of contraception should be used.  Spermatogenesis cycle is approximately 90 
days.
Highly Effective Methods bThat Are User Dependent 
 Combined (estrogen -and progestogen -containing) hormonal contraception associated with inhibition of 
ovulatio nc
oral
intravaginal
transdermal
injectable
 Progestogen -only  hormone contraception associated with inhibition of ovulation c
oral
injectable
 Sexual abstinence
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study intervention.  The reliability of sexual 
abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of 
the participant.
aContraceptive use by men or women should be consistent with local regulations re garding the use of 
contraceptive methods for those participating in clinical studies.
bFailure rate of <1% per year w hen used consistently and correctly.  Typical use failure rates differ from those 
when used consistently and correctly.
cIf locally  required, in accordance with Clinical Trial Facilitation Group guidelines, acceptable contraceptive 
methods are limited to those which inhibit ovulation as the primary mode of action.
Note:  Periodic abstinence (calendar, symptothermal, post -ovulation met hods), withdrawal (coitus interruptus), 
spermicides only, and lactational amenorrhea method are not acceptable methods of contraception for this study.  
Male condom and female condom should not be used together (due to risk of failure with friction) .
CONFIDENTIAL I3Y-MC-JPCY (b)
83Collection of Pregnancy Information
Male participants wi th partners who become pregnant
The invest igator will attempt to collect pregnancy informat ion on any male participant’s 
female partner who becomes pregnant while the male participant is in this study .This 
applies only to male participants who receive study  intervent ion.
After obtaining the necessary  signed informed consent from the pregnant female partner 
directly, the invest igator will record pregnancy information on the appropriate form and 
submit it to the sponsor within 24 hours of learning of the partner’s pregnancy .The 
female partner will also be fo llowed to determine the outcome of the pregnancy. 
Inform ation on the status of the mother and child will be forwarded to the sponsor. 
Generally, the fo llow-up will be no l onger than 6 to 8 weeks fo llowing the estimated
delivery  date. Any terminat ion of the pregnancy  will be reported including fetal status 
(presence or absence of ano malies) or indicat ion for the procedure. 
CONFIDENTIAL I3Y-MC-JPCY (b)
8410.5. Appendix 5: Liver Safety: Suggested Actions and Follow -up 
Assessments 
Selected tests m ay be obtained in the event of a treatment -emergent hepatic abnormalit y and may  
be required in fo llow-up wi th participant s in consultat ion with the Lilly CRP/CRS.
Hepatic Evaluation Testing –Refer to protocol Hepatic Safety Monitoring Section 8.2.2.1 for guidance on 
appropriate test selection.
For testing selected, analysis is required to be completed by the Lilly designated central labora tory except 
for Microbiology.
Local testing may be performed in addition to central testing when required for immediate patient 
management.
Results will be reported if a validated test or calculation is available.
Hematology Clinical Chemistry
Hemoglobin Total bilirubin
Hematocrit Direct bilirubin
Erythrocy tes (RBCs -Red Blood Cells) Alkaline phosphatase (ALP)
Leukocytes (WBCs -White Blood Cells) Alanine aminotransferase (ALT)
Differential: Aspartate aminotransferase (AST)
Neutrophils, segmented Gamma -glutamyl transferase (GGT)
Lymphocy tes Creatine kinase (CK)
Monocytes Other Chemistry
Basophils Acetaminophen
Eosinophils Acetaminophen Protein Adducts
Platelets Alkaline Phosphatase Isoenzymes
Cell morphology (RBC and WBC) Ceruloplasmin
CoagulationCopper
Ethyl Alcohol (EtOH)
Prothrombin Time, INR (PT -INR) Haptoglobin
Serology Immunoglobulin A ( IgA [ Quantitative ])
Hepatitis A Virus (HAV) Testing: Immunoglobulin G ( IgG [ Quantitative ])
HAV Total Antibody Immunoglobulin M ( IgM [ Quantitative ])
HAV IgM Antibody Phosphatidylethanol (PEth)
Hepatis B Virus (HBV) Testing: Urine Chemistry
Hepatitis B surface antigen (HBsAg) Drug Screen
Hepatitis B surface antibody (Anti -HBs) Ethyl glucuronide (EtG)
Hepatitis B core total antibody (Anti -HBc) Other Serology
Hepatitis B core IgM antibody Anti- nuclear antibody (ANA)
CONFIDENTIAL I3Y-MC-JPCY (b)
85Hepatitis B core IgG antibody Anti-smooth muscle antibody (ASMA)a
HBV DNAd Anti- actin antibodyb
Hepati tis C Virus (HCV) Testing: Epstein -Barr Virus (EBV) Testing:
HCV antibody EBV antibody
HCV RNA d EBV DNA d
Hepatitis D Virus (HDV) Testing: Cytomegalovirus (CMV) Testing:
HDV antibody CMV antibody
Hepatitis E Virus (HEV) Testing: CMV DNA d
HEV IgG antibody Herpes Simplex Virus (HSV) Testing:
HEV IgM antibody HSV (Type 1 and 2) antibody
HEV RNA d HSV (Type 1 and 2) DNA d
Microbiology c Liver Kidney Microsomal Type 1 (LKM -1) Antibody
Culture:
Blood
Urine
Abbreviations:  CRF = case report form; CRP = clinical research physician; CRS = clinical research scientist ; DNA 
= deoxy ribonucleic acid; Ig = immunoglobulin; INR = international normalized ratio; RNA = ribonucleic acid. 
a This is not required if Anti -Actin Antibody is tested.
b This is not required if Anti -smooth muscle antibody (ASMA) is tested.
c  Assayed by Investigator -designated local laboratory ONLY; no Central Testing available.   For some abnormal lab 
values, only the related diagnosis will be reported in the CRF .
d Reflex/confirmation dependent on regulatory requirements and/or testing availability.
CONFIDENTIAL I3Y-MC-JPCY (b)
8610.6. Appendix 6: Inducers and Strong Inhibitors of CYP3A
The informat ion in this table is provided for guidance to invest igators and does not preclude the 
use of these medicat ions if clinically indicated.
Strong Inducers of CYP3A
Carbamazepine
Dexamethasonea
Phenobarbital/phenobarbitone
Phenyto in
Rifapent ine
Rifampin
Rifabut in
St John’s wort
Moderate Inducers of CYP3A
Bosentan
Lesinurad
Modafinil
Primidone
Telotristat ethyl
Strong Inhibitors of CYP3A
Aprepitant
Ciprofl oxacin
Clarithromycin
Conivaptan
Diltiazem
Erythromycin
Fluconazo le
Itraconazole
Ketoconazo le
Nefazodone
Posaconazole
Troleando mycin
Verapamil
aImpo rtant note: All patients may receive supportive therapy with dexamethasone, preferably <=7 days, if clinically 
indicated.
Abbreviations:  CYP = cytochrome P450 .
CONFIDENTIAL I3Y-MC-JPCY (b)
8710.7. Appendix 7: CTCAE 5.0 Diarrhea /Pneumonitis /ALT and AST Increased Definition s
Diarrhea /Pneumonitis/ALT and AST Increased will be evaluated in this study  using the criteria proposed by CTCAE v 5.0 revised:  
Gastrointestinal disorders , Respi ratory , Thoraci c and Mediastinal Disorders ,and Invest igations.
Grade
Adverse Event 1 2 3 4 5
Gastrointestinal Disorders
DiarrheaIncrease of <4 stools per 
day over baseline; mild 
increase in ostomy output 
compared to baselineIncrease of 4 -6 stools per 
day over baseline; 
moderate increase in 
ostomy output compared 
to baseline ; limiting 
instrumental ADLIncrease of ≥7 stools per 
day over baseline; 
hospitalization indicated; 
severe increase in ostomy 
output compared to 
baseline; limiting self -care 
ADLLife-threatening consequences; 
urgent intervention indicatedDeath
Definitio n:  a disorder characterized byan increase in frequen cyand/or loose watery bowel movements
Respiratory, Thoracic, and Mediastinal Disorders
PneumonitisAsymptomatic; clinical or
diagnostic observations 
only;
interventio n not indicatedSymptomatic; medical
interventio n indicated;
limiting instrumental 
ADLSevere symptoms; limiting 
self-care ADL; oxygen 
indicatedLife-threatening respiratory 
compromise; urgent 
interventio n indicated (e.g., 
tracheotomy or intubation)Death
Definitio n:  A diso rder characterized by inflammation focally or diffusely affecting the lung parenchyma.
Investigations
Alanine 
aminotransferase 
(ALT) increased >ULN -3.0 x ULN if 
baseline was normal; 1.5 -
3.0 x baseline if baseline 
was abnormal>3.0 -5.0 x ULN if 
baseline was normal; >3.0 
-5.0 x baseline if baseline 
was abnormal>5.0 -20.0 x ULN if 
baseline was normal; >5.0 -
20.0 x baseline if baseline 
was abnormal>20.0 x ULN if baseline was 
normal; >20.0 x baseline if 
baseline was abnormalDeath
Definitio n: A finding based on laboratory test results that indicate an increase in the level of alanine aminotransferase (ALT or SGPT) in ablood specimen.
Aspartate 
aminotransferase 
(AST) increased>ULN -3.0 x ULN if 
baseline was normal; 1.5 -
3.0 x b aseline if baseline 
was abnormal>3.0 -5.0 x ULN if 
baseline was normal; >3.0 
-5.0 x baseline if baseline 
was abnormal>5.0 -20.0 x ULN if 
baseline was normal; >5.0 -
20.0 x baseline if baseline 
was abnormal>20.0 x ULN if baseline was 
normal; >20.0 x baseline if 
baseline was abnormalDeath
Definitio n: A finding based on laboratory test results that indicate an increase in the level of aspartate aminotransferase (AST or SGOT) in a blood specimen.
Abbreviation:  ADL = activities of daily living ; SGOT = serum glutamic -oxaloacetic transaminase; SGPT = serum glutamic -pyruvic transaminase; ULN = upper limit of 
normal
CONFIDENTIAL I3Y-MC-JPCY (b)
8810.8. Appendix 8: Abbreviations
Term Definition
ADT androgen deprivation therapy
AE adverse event
AI Aromatase inhibitor
ALT alanine aminotransferase
AR androgen receptor
AST aspartate aminotransferase
ATP adenosine triphosphate
BOR best overall response
CDK cyclin -dependent kinase
CDK 4&6 cyclin -dependent kinase s4 & 6
CI confidence interval
CIOMS Council forInternational Organizations ofMedical Sciences
CNS central nervous system
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all study -related, good clinical practice (GCP), and applicable regulatory 
requirements.
CR complete response
CRP clinical research physician: Individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, global safety physician or other medical officer.
CRPC castration -resistant prostate cancer
CRS clinical research scientist
CT computed tomography
CTCAE Common Terminology Criteria for Adverse Events
CYP cytochrome p450
DES diethy lstilbestrol
CONFIDENTIAL I3Y-MC-JPCY (b)
89Term Definition
DMC data monitoring committee
DSM T Developmental Safety Management Team
DSST Developmental Safety Surveillance Team
ECG electrocardiogram
ECOG
eCOAEastern Cooperative Oncology Group
electronic Clinical Outcome Assessment
eCRF electronic case report form
EDC electronic data capture
EMA European Medical Agency
enroll The act of assigning a participant to a treatment.  Participants who are enrolled in the 
study are those who have been assigned to a treatment.
enter Participants entered into a study are those who sign the informed consent form directly 
orthrough their legally acceptable representatives.
EORTC QLC -C30 European Organization for the Research and Treatment of Cancer Quality of Life 
Questionnaire
ERB Ethical review boards
FACT -G Functional Assessment of Cancer Therapy -General
FACT -GP5 GP5 item of the Functional Assessment of Cancer Therapy -General instrument, which 
asks participants to report the extent to which “(they are) bothered by side -effects of 
treatment”
FDA Food and Drug Administration
GCP good clinical practice
GFR glomerular filtration rate
GnRH gonadotropin -releasing hormone
GnRHa gonadotropin -releasing hormone agonist or antagonist
HER2 - human epidermal growth factor receptor 2 negative
HR+ hormone receptor positive
IB Investigator’s Brochure
ICF informed consent form
CONFIDENTIAL I3Y-MC-JPCY (b)
90Term Definition
ICH International Council for Harmonisation
IEC Independent Ethics Committees
IHC immunohistochemistry
ILD Interstitial lung disease
Informed consent A process by which a participant voluntarily confirms his or her willingness to 
participate in a particular study, after having been informed of all aspects of the study 
that are relevant to the participant’s decision to participate.  Informed consent is 
documented by means of a written, signed and dated informed consent form .
interim analysis An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.
investigational 
productA pharm aceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed pro ducts used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.
IRB Institutio nal Review Boards
IV intravenous
MATE multidrug and toxin extrusion
MBC metastatic breast cancer
mCRPC metastatic castration -resistant prostate cancer
MedDRA Medical Dictionary for Regulatory Activities
mHSPC metastatic hormone -sensitive prostate cancer
MRI magnetic resonance imaging
NHA Novel hormonal agent
nmCRPC non-metastatic castration -resistant prostate cancer
NRS Numeric Rating Scale
ORR objective response rate
OS overall survival
participant Equivalent to CDISC term “subject”: an individual who participates in a clinical trial, 
either as recipient of an investigational medicinal product or as a control
PCa prostate caner
CONFIDENTIAL I3Y-MC-JPCY (b)
91Term Definition
PCWG3 Prostate Cancer Clinical Trials Working Group 3
PET positron emission tomography
PFS progression -free survival
PK pharmacokinetics
PPS per-protocol set:  The set of data generated by the subset of participant who sufficiently 
complied with the protocol to ensure that these data would be likely to exhibit the 
effects of treatment, according to the underlying scientific model.
PR partial response
pRb retinoblastoma protein
PRO patient reported outc ome
PRO -CTCAE patient reported outcome -common terminology criteria for adverse events
PSA prostate -specific antigen
PT Preferred Term
QoL Quality  of Life
Rb retinoblastoma gene
RECIST Response Evaluation Criteria in Solid Tumors
RP2D recommended phase 2 dose
rPFS radiographic progression free survival
SAE serious adverse event
SAP statistical analysis plan
screen The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study.
SD stable disease
SoA Schedule of Activities
SOC System Organ Class 
SSE symptomatic skeletal event
SUSARs suspected unexpected serious adverse reactions
TBL total bilirubin
CONFIDENTIAL I3Y-MC-JPCY (b)
92Term Definition
TEAE Treatment -emergent adverse event: An untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, and does not necessarily have to have a causal relationship 
with this treatment.
TTE time to event
VTE venous thromboembolic events
CONFIDENTIAL I3Y-MC-JPCY (b)
9310.9. Appendix 9: Protocol Amendment History
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the Table of Contents (TOC).
Amendment a ( 24September 2020) 
This amendment is considered to be substant ial based on the cri teria set forth in Art icle 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council o f the European Unio n.
Overall Rationale for the Amendment:
This amendment incorporates chan ges in response to regulators’ comments.   In addition, this 
amendment includes changes made to clarify  information for sitesand m inor grammat ical, 
formatting, or spelling edits.
Section # and Name Description of Change Brief Rationale
1.2 Schema Clarification of Primary 
EndpointAdministrative
1.3 Schedule of Activities Added m obile healthcare 
service option to collect 
and process labsamplesProtocol flexibility
1.3.1 Sampling Schedule for 
Pharmacokinetics and BiomarkersAdded m obile healthca re 
service option to collect 
and process
pharmacokinetic (PK) 
and biomarker 
plasma /blood samplesProtocol flexibility
1.3.1 Sampling Schedule for 
Pharmacokinetics and BiomarkersAdded blood 
microsampling to PK 
sampling schedule Added blood microsampling
instructio ns  
2.3.1 Benefit Assessment Updated new treatment 
options for m etastatic 
castration -resistant 
prostate cancer (mCRPC) 
where approvedIn response to regulators’ comments
5.1 Inclusion Criteria Clarification of Inclusion
Criterio n #1 to indica te 
participants’ suitability
for experimental therapyIn response to regulators’ comments
5.2 Exclusion Criteria Clarification on prior Administrative 
CONFIDENTIAL I3Y-MC-JPCY (b)
94investigational agent
5.3 Lifestyle Considerations Text was added to caution 
participants with known 
hypersensitivity or 
suspected intolerance to 
abemaciclib or any of its 
excipientsIn response to regulators’ comments
6.1 Study Intervention(s) Administered Clarification on missed or 
vomited dosesAdministrative
6.2 
Preparation/Handling/Storage/AccountabilityClarification on study 
personnel responsibilities 
regarding study drugAdministrative 
6.2.1 Selection and Timing of Doses Clarification to indicate
that additio nal study  
treatment may be 
dispensed for planned 
delaysAdministrative
6.5 Concomitant Therapy Clarification to refer to 
prescribing information 
for concomitant 
medicationsIn response to regulators’ comments
7.2.1 Discontinuation of Inadvertently 
Enrolled PatientsClarification on 
discontinuation of 
inadvertently  enrolled 
patientsAdministrative
7.3 Lost to Follow up Clarification on 
designated study 
personnelAdministrative
8.1.1 Definitions of Efficacy Measures Clarification was 
provided on definition of 
“Objective Response 
Rate” and for 
consistency, “Disease 
Control RateIn response to regulators’ comments
8.2.1 Clinical Safety Laboratory 
AssessmentsClarification on study 
personnel and 
responsibilities for 
designating local lab and Administrative
CONFIDENTIAL I3Y-MC-JPCY (b)
95reporting of AEs. 
8.5 Pharmacokinetics Updated PK collection 
instructio nsAdded blood microsampling 
instructio ns 
8.8.1 Tissue Samples for Biomarker 
ResearchRem oved requirement of 
discussion with Lilly 
clinical research 
physician/scientist 
(CRP/CRS) for archival 
tissue Administrative
8.10. 2 Health Care Resource Utilization Clarification on 
autho rized study  
personnel Administrative 
9.2 Sample Size Determination Clarification on 
“Objective Response”Editorial
9.4.2 Primary Analysis Clarification was 
provided on definition of 
“Objective Response 
Rate”Administrative
10.1.1 Regulatory and Ethical 
ConsiderationsClarification on 
investigator study 
oversight and 
responsibilities Administrative
10.1.6 Data Quality Assurance Updated instructions for 
data capture of eCOAAdministrative
10.2 Appendix 2:  Clinical Laboratory tests Rem oved “recorded” typo Editorial
CONFIDENTIAL I3Y-MC-JPCY (b)
9611. References
Armstrong AJ,Szmulewi tz RZ ,Petrylak DP ,Holzbeierlein J ,Villers A , Azad A, Alcaraz A ,
Alekseev B ,Iguchi T ,Shore ND ,Rosbrook B ,Sugg J ,Baron B ,Chen L,Stenzl A .ARCHES: 
arandomized, phase III study  of androgen deprivatio n therapy  with enzalutamide or placebo in 
men with metastatic hormone -sensi tive prostate cancer. J Clin Oncol . 2019 ;37(32):2974 -2986.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jema l A.Globalcancer statist ics2018 : 
GLOBOCAN est imates of incidence and mortalit y worl dwide for 36 cancers in 185 countries.
CACancer J Clin . 2018; 68(6):394 -424.
ChiKN, Taavi tsainen S, Iqbal N, Ferrari o C, Ong M, Wadhwa D, Hotte SJ, Lo G, Tran B, Azad
A,WoodL, Gingerich JR, North S, Pezaro CV, Ruether D, Sridhar SS, Annala M, Baco n J, 
Wyatt AW. A rando mized phase 2 study of cabazi taxel (CAB) vs (ABI) abiraterone or (ENZ) 
enzalutamide in poor prognosis metastati c castration -resistant prosta te cancer. Annals of 
Oncology . 2018 ;29(suppl 8):viii271 -viii302.
Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury  S, Coskinas X, Fry denberg 
M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, 
McJannett M, North SA, Parnis F , Parul ekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, 
Tan TH, Thomson A, Tu E, Vera -Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, 
Sweeney CJ; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital 
andProstate Cancer Trials Group . Enzalutamide wit h standard first -line therapy in metastatic 
prostate cancer. N Eng J Med. 2019;381(2):121 -131.
de Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, Wülfing C, Kramer G, Eymard JC, 
Bamias A, Carles J, Iacovelli R, Melichar B, Sverrisdóttir Á, Theodore C, Feyerabend S, 
Helissey C, Ozatilgan A, Geffriaud -Ricouard C, Castellano D ,CARD Invest igators. 
Cabazitaxel versus abiraterone or enzalutamide in metastati c prostate cancer. N Eng lJ Med . 
2019; 381(26):2506 -2518.
Dickler MN, Tolaney SM, Rugo HS, Cortés J, Diéras V, Patt D, Wildiers H, Hudis CA, 
O'Shaughnessy J, Zamora E, Yardley  DA, Frenzel M, Kousteni s A, Baselga J. MONARCH 1, 
a phase II study  of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients 
with refracto ry HR+/HER2 − metastati c breast cancer. Clin Cancer Res .2017;23(17):5218 -
5224.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, 
Gwy therS, Mooney  M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Laco mbe D, Verweij J. 
New response evaluat ion criteria in so lid tumo urs: revised RECIST guideline (versio n 1.1). 
Eur J Cancer. 2009;45(2):228 -247.
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Po lyakov S, Jievaltas M, Luz M, Alekseev 
B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith MR, ARAMIS Invest igators. 
Darol utamide in nonmetastatic, castration -resistant prostate cancer. N Engl J Med . 
2019a;380(13):1235 -1246.
Fizazi K, Tran N, Fein L, Matsu bara N, Rodriguez -Antolin A, Alekseev BY, Özgüroğlu M, Ye 
D, Fey erabend S, Protheroe A, Sulur G, Luna Y, Li S, Mundle S, Chi KN. Abiraterone acetate 
plus prednisone in pat ients with newly  diagnosed high -risk m etastati c castrati on-sensit ive 
CONFIDENTIAL I3Y-MC-JPCY (b)
97prostate cancer (LATITUDE ): final overall survival analysis o f a randomised, double -blind, 
phase 3 trial. Lancet Oncol . 2019 b;20(5):686 -700.
Goetz MP, Martin M, Di Leo A, Im SA, Awada A, Forrester T, Frenzel M, Cox J, Barriga S, Toi
M, Iwata H, Johnston S. MONARCH 3: Abemaciclib as init ial therapy  for pati ents wi th HR+,
HER2 -advanced breast cancer –Results fro m the prepl anned final PFS analysis [abstract] . In: 
Proceedings of the American Associ ation for Cancer Research Annual Meeting 2018 ; 2018 
Apr 14 -18; Chicago, IL . Philadelphia (PA): AACR; Cancer Res .2018;78(13 Suppl): Abstract 
CT040. https://doi.org/ 10.1158/1538- 7445.AM2018 -CT040
Hamilton E,CortesJ,Dieras V,Ozyilkan O,Chen S-C,Petrakova K,Manikhas A,Jerusalem G,
Hegg R,LuY,Bear MM, Johnston EL,Marti n M. nextMONARCH 1: phase 2 study  of 
abemaciclib plus tamoxifen or abemaciclib alo ne in HR+, HER2- advanced breast cancer
[abstract] .Cancer Res.2019 ;79(suppl 4).Abstract PD1-11. https://doi .org/10.1158/1538 -
7445.SABCS18 -PD1-11
Higano CS, Sternberg CN, Saad F, Tombal BF, Miller K, Kalino vsky J, Jiao XL, Tangi rala K, 
Sartor AO. Treatment patterns and outcomes for metastatic castrati on-resistant prostate cancer 
(mCRPC ) in a real -world setting: aretrospective study  of greater than 2500 p atients [abstract] .
JClin Onc ol. 2019;37( suppl  7):256. Abstract 256.
https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.7_suppl.256
Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, Ivashchenko P , Demirhan E, 
Model ska K, Phung, Krivoshik A, St ernberg CN. Enzalutamide in men with nonmetastatic, 
castration -resistant prostate cancer. N Engl J Med . 2018;378(26):2465-2474.
James ND, Spears MR, Clarke NW, Dearnaley DP, Mason MD, Parker CC, Ritchie AW, Russell 
JM, Schiavone F, Attard G, de Bono JS, Bi rtleA, Engeler DS, Elliott T, Matheson D, 
O’Sullivan J, Pudney D, Srihari N, Wallace J, Barber J, Syndikus I, Parmar MK, Sydes M R, 
STAMPEDE Investigators . Failure -free survival and radiotherapy  in pat ients with newly  
diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the 
STAMPEDE trial. JAMA Oncol . 2016;2(3):348 -357.
James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley  DP, Ri tchie AWS, 
Amos CL, Gilson C, Jones RJ, Matheson D, Millman R, Attard G, Chowdhury  S, Cross WR, 
Gillessen S, Parker CC, Russell JM, Berthold DR, Brawley C, Adab F, Aung S, Birt le AJ, 
Bowen J, Brock S, Chakraborti P, Ferguson C, Gale J, Gray  E, Hingorani M, Hoskin PJ, 
Lester JF, Malik ZI, McKinna F, McPhail N, Mone y-Kyrle J, O'Sullivan J, Parikh O, 
Protheroe A, Robinson A, Srihari NN, Thomas C, Wagstaff J, Wylie J, Zarkar A, Parmar 
MKB, Sy des MR , STAMPEDE Invest igators. Abiraterone for prostate cancer not previously 
treated with hormone therapy. N Engl J Med .2017; 377(4):338 -351.
Johnston S, Martin M, Di Leo A, Im SA, Awada A, Forrester T, Frenzel M, Hardebeck MC, Cox 
J, Barriga S, Toi M, Iwata H, Goetz MP. MONARCH 3 PFS: a randomized study of 
abemaciclib as init ial therapy for advanced breast cancer. NPJ Breast Cancer . 2019;5:5.
Kaplan EL, Meier P. Nonparametric estimat ion from incomplete observat ions. J Amer Stat 
Assoc . 1958;53(282) :457-481.
CONFIDENTIAL I3Y-MC-JPCY (b)
98Knudsen ES, Pazzagli C, Born TL, Bertolaet BL, Knudsen KE, Arden KC, Henry RR, Feramisco 
JR. El evated cyclins and cyclin -dependent kinase activit y in the rhabdo myosarcom a cell line 
RD. Cancer Res . 1998;58(9):2042- 2049.
Lonergan PE, Tindall DJ. Androgen receptor signaling in prostate cancer development and 
progression. J Carcinog. 2011;10:20.
[NCI] National Cancer Inst itute. Commo n Terminology  Criteria for Adverse Events (CTCAE) 
v5.0. Available at: 
https://ctep.cancer.gov/protocolDevelopment/electronic_applicat ions/ctc.ht m#ctc_50. 
Published on 27 November 2017. Accessed October 07, 2019.
Noonan KL,North S ,Bitting RL ,Armstrong AJ ,Ellard SL ,Chi KN . Clinical act ivity of 
abiraterone acetate in pat ients with metastati c castrati on-resistant prostate cancer progressing 
after enzalutamide. Ann Oncol . 2013;24(7):1802 -1807.
Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M , Kantoff PW, Sonpavde G, Sternberg CN, 
Yegnasubramanian S, Antonarakis ES. Update on systemic prostate cancer therapies: 
management of metastati c castrati on-resistant prostate cancer in the era of precisi on oncology.
Eur Urol .2019;75(1):88 -99.
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicit y 
and response criteria of the Eastern Cooperative Onco logy Group. Am J Clin Oncol . 
1982;5(6):649 -655.
Ortega S, Malumbres M, Barbacid M. Cyclin D -dependent kinases, INK4 inhibitors and cancer. 
Biochim Biophys Acta . 2002;1602(1):73 -87.
PalSK, Patel  J, He M, Foul k B, Kraft K, Smirnov DA, Twardowski P, Kortylewski M, Bhargava 
V, Jones JO. Identificat ion of mechanisms of resistance to treatment with abiraterone acetate 
or en zalutamide in patients with castration- resistant prostate cancer (CRPC). Cancer . 
2018;124(6):1216 -1224.
Patnai k A, Rosen LS, Tol aney SM, Tolcher AW, Goldman JW, Gandhi L, Papadopoulos KP, 
Beeram M, Rasco DW, Hilton JF, Nasir A, Beckmann RP, Schade AE, Fulf ord AD, Nguy en 
TS, Marti nez R, Kulanthaivel P, Li LQ, Frenzel M, Cronier DM, Chan EM, Flaherty  KT, Wen
PY, Shapi ro GI. Efficacy  and safety  of abemaciclib, an inhibitor of CDK4 and CDK6, for 
patients wi th breast cancer, non -small  cell lung cancer, and other solid tumors. Cancer Discov . 
2016;6(7):740 -753.
Scher HI ,Morris MJ ,Stadler WM ,Higano C ,Basch E ,Fizazi K ,Antonarakis ES ,Beer TM ,
Carducci MA ,Chi KN,Corn PG ,de Bono JS ,Dreicer R ,George DJ ,Heath EI ,Hussain M ,
Kelly WK ,Liu G,Logothetis C ,Nanus D ,Stein MN ,Rathkopf DE ,Slovin SF ,Ryan CJ ,
Sartor O ,Small EJ, Smith MR ,Sternberg CN, Taplin ME ,Wilding G, Nelson PS ,Schwartz 
LH,Halabi S,Kantoff PW ,Armstrong AJ , Prostate Cancer Clinical TrialsWorking Group 3.
Trial design and objectives for castrati on-resistant p rostate cancer: updated recommendat ions 
from the prostate cancer clinical trials working group 3. J Clin Oncol . 2016 ;34(12):1402 -1418.
Schrader AJ, Boegemann M, Ohlmann CH, Schnoeller TJ, Krabbe LM, Hajili T, Jentzmik F, 
Stoeckl e M, Schrader M, Herrm ann E, Cronauer MV. Enzalutamide in castration -resistant 
prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol .
2014; 65(1):30 -36.
CONFIDENTIAL I3Y-MC-JPCY (b)
99Sherr CJ. Cancer cell cycles. Science . 1996;274(5293):1672 -1677.
Sledge GW Jr ., Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, 
Kaufman PA, Koh H, Grischke EM, Frenzel M, Lin Y, Barriga S, Smit h IC, Bouray ou N, 
Llombart-Cussac A. MONARCH 2: abemaciclib in co mbination wit h fulvestrant in wo men 
with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine 
therapy . J Clin Oncol .2017;35(25):2875 -2884.
Sledge GW Jr, Toi  M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, 
Kaufman PA, Koh H, Grischke EM, Conte P, Lu Y, Barriga S, Hurt K, Frenzel M, Johnston S, 
Llombart-Cussac A. The effect of abemaciclib plus fulvestrant on overall survival in hormone 
receptor -positive, ERBB2 -negat ive breast cancer that progressed on endocrine therapy -
MONARCH 2: A ran domized clinical tri al. JAMA Oncol . 2020;6(1):116 -124. 
Smith TJ, Bohl ke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, 
Khatcheressian JL, Leighl NB, Perkins CL, Somlo  G, Wade JL, Wozniak AJ, Armitage JO ,
American Societ y of Clinical  Oncol ogy.Reco mmendat ions for the use of WBC growth 
factors: American Societ y of Clinical  Oncol ogy clinical practice guideline update. J Clin 
Oncol . 2015;33(28):3199- 3212.
SmithMR, Saad F, Rathkopf DE, Mulders PFA, de Bono JS, Small EJ, Shore ND, Fizazi K, 
Kheoh T, Li J, De Porre P, Todd MB, Yu MK, Ryan CJ. Clinical outcom es from androgen
signaling -directed therapy after treatm ent wi th abiraterone acetate and prednisone in patients 
with metastati c castrati on-resistant prostate cancer: post hoc analys is of COU -AA-302. Eur 
Urol . 2017;72(1):10 -13.
Smith MR, Saad F, Chowdhury  S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring 
PN, Lee JY, Uemura H, Lopez -Gitlitz A, Trudel  GC, Espina BM, Shu Y, Park YC, Rackoff 
WR, Yu MK, Small EJ, SPARTAN Invest igators. Apal utamide treatm ent and m etastasi s-free 
survival in prostate cancer. N Engl J Meg . 2018;378(15):1408- 1418.
Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, 
Kohli M, Cooney  MM, Drei cer R, Vogel zang NJ, Pi cus J, Shevrin D, Hu ssain M, Garcia JA, 
DiPaola RS. Chemo horm onal therapy in metastati c horm one-sensi tive prostate cancer. N Engl 
J Med . 201 5;378(8):737 -746.
Trask PC, Dueck AC, Piault E, Cam pbell A.Patient -reported outcomes versio n of the commo n 
termino logy criteria for adverse events: methods for i tem select ion in industry -sponsored 
oncol ogy clinical  trials. Clinical Trials. 2018; 15(6):616-623.
Xu Y, Chen SY, Ross KN, Balk SP. Androgens induce prostate cancer cell pro liferat ion through 
mammalian target of rapamycin act ivation and post -transcript ional increases in cyclin D 
proteins. Cancer Res. 2006;66(15):7783 -7792.
Leo Document ID = dfa00326-6bb9-406f-a51e-3b53a7e10a0d
Approver:
Approval Date & Time: 04-Mar-2021 15:43:17 GMT
Signature meaning: Approved
Approver:
Approval Date & Time: 04-Mar-2021 21:33:24 GMT
Signature meaning: Approved
PPD
PPD